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ABSTRACT 
UNDERSTANDING STRUCTURE-PROPERTY RELATIONSHIPS AT THE 
NANO-BIO INTERFACE FOR DELIVERY APPLICATIONS 
SEPTEMBER 2014 
KRISHNENDU SAHA, B.Sc., JADAVPUR UNIVERSITY 
M.Sc., INDIAN INSTITUTE OF TECHNOLOGY MADRAS 
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Vincent M. Rotello 
The surface chemistry of the nanomaterials creates an effective interface between two 
entirely different worlds: nanotechnology and biology. Understanding the interaction between 
nanomaterial surface chemistry and biological entities can be useful for a wide variety of 
biomedical applications as well as can provide crucial information for nanotoxicology. In my 
research, I have used gold nanoparticles as a model platform to synthesize a family of 
nanoparticles with atomic level control of their surface properties and probe their interaction with 
biological systems. First part of my research focused on the understanding the uptake 
mechanisms, toxicity, and hemolytic properties of cationic nanoparticles, an excellent gene 
delivery vectors, and provide design parameters to avoid toxic consequences. In the second part 
of my research, a new class of surface engineered antifouling nanomaterials were fabricated that 
can eschew plasma protein binding, providing opportunity to interrogate nano-biological behavior 
without any complications arising from the protein binding to nanomaterial surface. Since the 
surface chemistry of nanoparticles dictates the interaction between nanomaterials and biological 
entities, the findings in this thesis can be generalized to nanomaterials with a wide of variety of 
core materials of unique physical properties. 
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CHAPTER 1  
NANOPARTICLES IN BIOLOGY 
1.1. An Overview of Nanobiotechnology 
The advent of nanotechnology in last two-three decades has opened up a new avenue of 
research areas. The great strength of nanotechnology relies on its strictly interdisciplinary nature; 
creation of new materials, understanding their properties, and apply them to solve important 
questions in materials science and biology. In particular, nanoparticles (size regime 1 to 100 nm) 
have numerous advantages in understanding biological systems as well as regulating numerous 
biological processes.1,2,3 These ‘tiny’ materials essentially commensurate the size of various bio-
macromolecules including protein and DNA and provide effective surface area/receptors for 
multivalent interaction.4 The high surface-to-volume ratio, tunable functionality and a wide 
variety of available core materials (metal/semiconductor) featuring magnetic and optoelectronic 
properties has led to develop nanoparticles for a variety of biological applications including 
macromolecular surface recognition,5,6 sensing,7,8,9, imaging,10,11,12 and drug/gene delivery 
13,14,15,16,17,18 for cancer therapy and tissue engineering applications.19,20  
Nanoparticles represent a synthetic intermediate between small molecule and 
macroscopic materials. They provide unique physicochemical properties compared to the bulk 
materials that make them attractive scaffolds for biomedical applications. In addition, the various 
size and shape-dependent synthesis of nanoparticles aided the study of their unique physical 
properties.21,22 These novel physical properties of nanoparticles generally come from their high 
surface area compared to the bulk materials; as a typical example- bulk gold have a bright yellow 
color, however, gold nanoparticles can be dark brown to purple to red based on the core size. In 
addition to the physical properties arising from the metal/semiconductor core, a wide variety of 
small molecule ligands can be appended to the nanoparticle surface that can act as a protective 
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layer to improve nanoparticle stability in physiological condition as well as it can be further 
engineered to give the nanoparticles tunable surface property. For example, thiol-functionalized 
ligands have a great affinity to the gold core and have been used to functionalize gold 
nanoparticles of various sizes.23 In addition, this thiol monolayer has further been engineered for 
sensing and delivery applications. Table 1.1 listed some well known core materials and 
corresponding surface ligands with their applications in various areas of nanobiotechnology. 
Table 1.1 Characteristics, ligands and representative applications for various metal and 
semiconductor materials (reproduced from reference 2). 
Core 
material 
Characteristics  Ligand(s) Applications 
Au Optical 
absorption, 
fluorescence and 
fluorescence 
quenching, 
stability 
Thiol, disulfide, 
phosphine, 
amine 
Biomolecular 
recognition, delivery, 
sensing 
Ag Surface-
enhanced 
fluorescence 
Thiol Sensing 
Pt Catalytic 
property 
Thiol, phosphine, 
amine, 
isocyanide 
Bio-catalyst, sensing 
CdSe Luminescence, 
photo-stability 
Thiol, phosphine, 
pyridine 
Imaging, sensing 
Fe2O3 Magnetic 
property 
Diol, dopamine 
derivative, amine 
MR imaging and 
biomolecule 
purification 
SiO2 biocompatibility Alkoxysilane Biocompatible by 
surface coating  
1.2. Nanoparticles as Delivery Vehicles 
Current pharmaceutical industry is based on the production of small molecule drugs that 
target mutated proteins, enzymes, ion channels, receptors, etc. to achieve a therapeutic effect for a 
particular disease. However, traditional pharmaceutical agents have several drawbacks including 
poor solubility, decomposition of drugs in vivo, poor pharmacokinetics (e.g. rapid renal clearance 
of drugs), and bioavailability.24,25 Drug delivery systems (DDSs) can overcome these issues, 
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providing better targeting efficacy and minimize side effects. Some important features of DDSs 
include improved targeting efficiency to the disease site by decorating DDSs surface with ligands 
specifically targeted to the disease cell surface receptors, sustained release of drugs thus 
maintaining effective concentrations of therapeutics with fewer dosing, and remote-controlled 
release of drugs from the DDS using external stimuli.26,27 Overall, DDSs provide the potential to 
enhance the drug safety while lowering unwanted side effects and improve patient compliance.28  
The design and synthesis of nanoscale materials with unique properties provide an 
opportunity to target complex diseases and address the complicated issues that was not well 
understood. Nanoparticle-based therapeutic systems are important synthetic modalities that 
showed tremendous potential as DDSs to target a number of deadly diseases including cancer. A 
number of nanotechnology-based cancer therapeutic products are already in the market and under 
clinical trials. Nanoparticle-based cancer therapeutics has shown improved efficacy compared to 
traditional medicine owing to the facts such as higher tumor site specificity, efficient cellular 
uptake, and increased payload delivery.29,30,31 Several physical and structural attributes of the 
nanoparticles provide these potential therapeutic efficiencies. First, smaller size (~10-100 nm) of 
the nanocarriers helps them to accumulate near tumor sites exploiting the enhanced permeability 
and retention (EPR) effect.32,33 Second, tunable surface properties allow efficient 
functionalization and increased circulation properties for desired therapeutic action. Third, high 
surface to volume ratio enables them to carry high payloads of single or multiple types of drug 
molecules to achieve simultaneous therapeutic outcome. For example, Zubarev et al. have 
demonstrated that a nanoparticle with 2 nm core diameter can load nearly 70 molecules of 
paclitaxel, a highly potent cancer drug.34 These nanocarries can increase the local concentration 
of drugs to the tumor site exploiting EPR effect and can be released using internal (pH) or 
external (light) triggers with proper surface engineering. Moreover, the multivalent interaction of 
the targeting ligands on the nanoparticle surface can interact preferentially with cancer cell-
surface receptors minimizing potential side effects of administrated drug molecules.35 The two 
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popular approaches in cancer nanomedicine to combat solid tumors are 1) passive targeting, and 
2) active targeting.36 Passive targeting strategies mostly rely on the EPR effect of tumor 
surrounding leaky blood vessels while active targeting exploits the tethering of the targeting 
ligands directed to a particular receptor over-expressed by target tumor cells. Numerous 
nanoparticle-based systems has currently been explored for cancer research including liposomes, 
polymeric nanoparticles, micelles, gold nanoparticles, etc. while few already got clinical approval 
from US Food and Drug Administration (FDA).37,38 
 
Figure 1.1. Monolayer protected gold nanoparticles used in this thesis work that feature a gold 
core, a hydrophobic organic monolayer to confer stability, an oligo(ethylene glycol) spacer to 
improve biocompatibility and solubility and a functional head group to probe the interaction of 
synthesized nanomaterials at the biological interface. 
 Gold nanoparticles (AuNPs) provide attractive features that have been exploited as 
excellent DDSs both in vitro and in vivo. First, the gold core is essentially inert and non-toxic.39,40 
Second, AuNPs can be synthesized with a wide variety of size and shapes in a straightforward 
manner with highly monodisperse fashion. This provides effectively tunable surface area/ligand 
coverage for drug loading and/or multivalent interaction with DNA/siRNA for intracellular 
delivery. Finally and perhaps the most importantly, the surface of AuNPs can be decorated with a 
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wide range of functionality including small molecule ligands, antibodies, peptides, etc. that can 
interact with the cancer cells. Due to these above mentioned attributes, AuNPs were used by 
several groups as drug/gene delivery carriers. In this thesis, surface engineered AuNPs were used 
to probe the effect of surface properties on the biological systems. Therefore a brief introduction 
to the synthesis and surface functionalization of monolayer protected AuNPs (Figure 1.1) and its 
relevant biological applications will be discussed in this chapter. 
1.3. Monolayer Protected Gold Nanoparticles (AuNPs) 
AuNPs have been widely used in biomedical applications due to their non-toxic core, 
straightforward synthesis, and tunable surface functionalization.41 The first synthesis of colloidal 
gold can be dated back to Michael Faraday’s work in 1857,42 however, significant boost in the 
synthesis of AuNPs was achieved after Turkevich developed a classic approach to synthesize 20 
nm AuNPs by reducing gold salt using sodium citrate.43 This is one of the most popular 
approaches to date to synthesize AuNPs in water with tunable size by simply varying the ratio of 
the gold salt to the sodium citrate.44 Although relatively easy, AuNPs synthesized in this method 
lack proper chemical functional groups that compromise their stability in the physiological 
condition, compromising their utility in biological applications. A significant breakthrough in the 
synthesis of highly stable AuNPs was achieved when Brust and Schriffin synthesized 
dodecanethiol monolayer protected AuNPs in organic solvent with diameter 1.5-5 nm. In this 
method, sodium borohydride (NaBH4) was used as a reducing agent and surfactant 
tetraoctylammonium bromide (TOAB) was used to transfer hydrogen tetrachloroaurate (HAuCl4) 
from aqueous phase to the organic phase.45 The size of AuNPs produced in this method can be 
readily controlled by varying the gold-to-thiol ratio, reduction rate, reaction temperature, time, 
etc.46,47,48 These AuNPs are highly stable due to the synergic effect of strong thiol-gold 
interactions and van der Waals attractions between the monolayer ligands. In addition, AuNPs 
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synthesized in this way can be thoroughly dried and re-dispersed without any aggregation, 
attesting to their superior stability over other AuNPs.  
  A wide variety of ligands/capping agents including amino acids,49 amines,50,51,52 
polymers53,54,55 have been used to yield AuNPs of different core sizes and dispersities. These 
stabilizing agents also provide the necessary barrier to avoid particle coalescence. Table 1.2 listed 
some of the most common approaches used to synthesize monolayer protected gold 
nanoparticles.56   
Table 1.2 Synthetic methods and capping agents for AuNPs of diverse core size (Reproduced 
from Ref 56).       
re size                 Synthetic methods Capping agents References 
1-2 nm Reduction of AuCl(PPh3) with diborane or 
sodium borohydride 
Phosphine 57,58 
1.5-5 nm Biphasic reduction of HAuCl4 by sodium 
borohydride in the presence of thiol 
capping agents 
Alkanethiol 45,47,48  
5-8 nm Reduction of HAuCl4 by sodium 
borohydride in the presence of TOAB 
Quaternary 
ammonium salt 
(TOAB) 
59 
8-20 nm Reduction of HAuCl4 by oleyl amine in 
water under heating 
Oleyl amine 50,60 
10-40 nm Reduction of HAuCl4 with sodium citrate in 
water 
citrate 43,44,61 
 
 The AuNPs produced by those capping agents listed on Table 1.2, however, are mostly 
soluble in organic solvent (except citrate) and most importantly lack chemical functionalities, 
thereby restricting their applications in biology. To solve this issue, Murray et al. developed a 
simple but efficient approach called place exchange (Figure 1.2) that can introduce chemical 
functional group on AuNP surface and provide water solubility.62 In this approach, the initially 
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thiol-stabilizing monolayer was exchanged with another thiol-anchoring ligand when the later is 
present in excess.63 Most importantly, using the place exchange reaction mixed monolayer 
AuNPs featuring two or more functional groups can also be tethered to the AuNP surface for 
synergistic applications. The reaction time and the feed ratio of the functional ligands further 
control the loading efficiency onto AuNPs surface. Using this place exchange reaction, several 
groups have developed water soluble AuNPs64 that have been used for a wide variety of 
biological applications including sensing65 and drug/gene delivery.66  
 
Figure 1.2. AuNP synthesis and surface functionalization via place exchange reaction. This 
strategy allowes to decorate AuNP monolayer with two or more of functional ligands for 
simultaneous applications. 
1.4. Cellular Interaction of Gold Nanoparticles  
     The key requirement of any DDSs is to overcome the cellular barrier and intracellular 
delivery of therapeutics. Therefore, having high intracellular uptake is an essential requirement of 
any delivery vehicles to successfully release the cargo inside the cells. Several critical factors 
dictate nanoparticle entry into the cells and a systematic understanding these factors can lead to 
develop delivery vehicles with improved therapeutic efficacy and low cytotoxicity. Nanoparticle 
size is a key determinant of particle uptake inside the cells. For example, Chan et al. have 
demonstrated that cellular uptake of AuNPs is strictly dependent on their size; 50 nm AuNPs 
showed the highest uptake compared to other sizes of AuNPs tested (14-100 nm).67 This 
particular size preference in uptake was also observed for other type of nanoparticles and was 
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thought to happen due to the enhanced receptor-mediated endocytosis of 50 nm nanoparticles 
over other sizes.68 In a follow-up study, Chan et al. fabricated AuNP-coated with Herceptin and 
tested for ErbB2 receptor-mediated internalization in breast cells. Likewise, the most efficient 
cellular uptake was observed with the 20~50 nm particles and programmed cell death (apoptosis) 
was enhanced by particles with 40–50 nm range.69 
 
Figure 1.3. Schematic representation of the interaction between gold NPs bearing different 
surface charge and SK-BR-3 breast cancer cells. (a) Citrate-coated (negative), (b) 
polyvinylalcohol-coated (neutral), and (c) poly(allyamine hydrochloride)–coated (positive) NPs 
(Adapted from Ref 3) 
Surface property of AuNPs perhaps plays the most important role in determining 
nanoparticle interaction with cells. For example, Xia et al. examined the role of surface charge on 
the internalization of gold NPs (Figure 1.3).70 In their findings, positively charged NPs were 
adsorbed more efficiently on the negatively charged cell surface and consequently showed greater 
internalization than that of neutral and negatively charged NPs. However, efficient intracellular 
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uptake of negatively charged NPs is also known, presumably through pinocytosis or membrane 
diffusion.71 Moreover, negatively charged quantum dots were shown to penetrate mouse skin, 
with higher degree of penetration observed upon exposure to UV light.72 Likewise, DNA 
functionalized anionic gold NPs were shown to penetrate in epidermis layer of mouse skin with 
no apparent inflammation or toxicity.73 
Two-dimensional cell culture models present a vastly different environment than tissues, 
complicating translation into in vivo systems. Rotello and Forbes et al. have demonstrated the role 
of NP surface charge for the delivery of covalently attached therapeutic drugs using a three-
dimensional cell culture model. Significantly, cationic particles showed delivery of drugs on the 
proliferating peripheral cells due to their higher uptake; however, anionic particles had higher 
diffusion rates, delivering drug- and fluorophore-tagged NPs more rapidly to the center of the 
spheroid model (Figure 1.4).74 
 
Figure 1.4. (a) Structure of mixed monolayer-protected cationic and anionic gold NPs loaded 
with thioalkylated fluorescein isothiocyanate (FITC). Green fluorescence images of tumor 
cylindroids treated with (b) cationic and (c) anionic particles. Adapted from Ref 3 and 74) 
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In addition to surface charge, NP hydrophobicity also plays an important role in the 
cellular uptake process. In one study, Mailänder et al. have demonstrated that increasing surface 
hydrophobicity of polymeric NPs increases intracellular uptake in a variety of cell lines.75 Rotello 
et al. have demonstrated a linear correlation of surface hydrophobicity and intracellular uptake of 
gold NPs (2 nm core), arising from a stronger interaction of hydrophobic NPs with serum 
albumin.76 However, in the absence of serum, no apparent trend between surface hydrophobicity 
and cellular uptake was found, demonstrating the importance of serum protein adsorption on the 
NP internalization process.  
Due to its high cellular uptake cationic AuNPs have successfully used in intracellular 
DNA delivery applications. In early work, Klibanov and Thomas used polyethyleneimine (PEI) 
functionalized AuNPs and to deliver plasmid DNA into mammalian cells.77 The most potent 
conjugates were 12 times more efficient at plasmid DNA delivery than their unmodified PEI 
counterparts. In an analogus example, Rotello et al. developed quaternary ammonium-
functionalized AuNPs as the effective intracellular delivery vehicles for plasmid DNA.78 These 
studies demonstrated that a number of parameters were important for successful transfection, 
including the AuNP surface charge coverage and hydrophobicity. Therefore cationic AuNPs 
provide a promising platform for gene delivery applications due to their high intracellular uptake 
and tunable transfection efficiency based on their surface functionality. 
1.4.1. Toxicity of Cationic Gold Nanoparticles 
The significant higher uptake of cationic AuNPs, however, comes with a potential cons. 
During the uptake process, cationic AuNPs can strongly interact with cell membrane leading to 
membrane rupture/cell lysis that can initiate apoptosis and/or necrosis pathway. In early studies 
on NP toxicity, Rotello et al. demonstrated that a cationic mixed monolayer protected cluster 
(NP1) showed higher cytotoxicity than its anionic analogue (NP2), demonstrating the key role of 
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surface charge on NP cytotoxicity (Figure 1.5a).79 Likewise, MMPC1 disrupted anionic 
phosphatidylcholine/phosphatidylserine vesicles more efficiently than MMPC2 due to the strong 
electrostatic interactions with the negatively charged lipid bilayer (Figure 1.5b). Similarly, 
alkylamine functionalized nanoparticles with 2 nm gold cores were shown to disrupt supported 
lipid bilayers (SLB).80 
 
Figure 1.5. Effect of functionalized AuNPs on the disruption of lipid bilayers. (a) Surface 
functionalized NP1 and NP2 and (b) Comparison of cationic NP1 and anionic NP2 (220 nM) in 
disrupting vesicles with an overall negative charge (SOPC/SOPC, L-R-stearoyloleoyl-
phosphatidylcholine/L-R-stearoyl-oleoyl-phospha-tidylserine). (Adapted from Ref 79 and 81). 
Mukherjee and Rotello et al. further investigated the role of NP surface charge on the cell 
membrane potential. Four AuNPs with varying surface charges (e.g. cationic, anionic, 
zwitterionic, and neutral) were incubated with cells (Figure 1.6a).82 Positively charged AuNPs 
depolarized the membrane potential in a dose dependent manner across different cell types 
compared to other NPs (Figure 1.6b). Furthermore, cationic AuNPs rapidly increased the 
intracellular Ca2+ concentration, [Ca2+]i by stimulating plasma membrane Ca2+ influx as well as 
Ca2+ release from the endoplasmic reticulum, with the concomitant inhibition of proliferation of 
human bronchial epithelial cells (BEC) and human airway smooth muscle cells (ASM) (Figure 
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1.6c).83 Taken together, positively charged AuNPs lead to perturbation of the cell membrane by 
structural reconstruction and phase transition of the lipid bilayer. Furthermore, they induce 
cytotoxicity and/or cell death due to intracellular signaling by changing the membrane potential 
and increasing [Ca2+]i. 
 
Figure 1.6. Effect of gold NPs with different surface charges on cellular membrane potential. (a) 
Cationic, anionic, neutral, and zwitterionic NPs. (b) Membrane potential changes following the 
exposure to NPs for ovarian cancer cells (CP70 and A2780), human bronchial epithelial cells 
(BEC), and human airway smooth muscle cells (ASM) using cell permeable fluorescent 
membrane potential indicator RH414 and real-time fluorescence microscopy. In addition, the 
extent of membrane potential change was analyzed in a cationic NP concentration dependent 
manner. (*p < 0.05) (c) Scheme of NP effects on cell and TEM of cationic NP interactions with 
plasma membrane. Adapted from Ref 82.  
Surface functionalized nanoparticles can cause immune responses84 and/or 
immunotoxicity through several mechanisms.85 In addition to surface charge, Rotello et al. have 
demonstrated that surface hydrophobicity of AuNPs dictates the immune response of splenocytes 
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(Figure 1.6).86 AuNPs (NP1-8) with different hydrophobicities (Figure 1.7a) showed a direct, 
quantitative correlation between hydrophobicity and immune activation related to the gene 
expression of cytokines (e.g. interferon (IFN)-γ, tumor necrosis factor (TNF)-α, interleukin (IL)-
2, 6, and 10). In particular, increasing the hydrophobicity of the NP surface elicited the increased 
the expression of TNF-α, a pro-inflammatory cytokine (Figure 1.7b), and the expression of IL-10, 
an anti-inflammatory cytokine (Figure 1.7c). 
 
Figure 1.7. Effect of AuNP surface hydrophobicity on gene expression related to immune 
response. (a) Surface functionalized AuNPs controlling the surface hydrophobicity and cytokine 
gene expression of (b) TNF- α in vitro and (c) IL-10 in vivo as a function of NP headgroup LogP. 
LogP represents the relative hydrophobic indices of the head group. Adapted from Ref 86.  
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1.5. Dissertation Overview 
Understanding the interaction of surface functionalized nanomaterials with biosystems 
can help in design materials with improved therapeutic efficacy and minimize unwanted side 
effects. In my research, I have employed a structure-activity based approach to probe, optimize, 
and develop new nanomaterials that can mitigate the common issues (toxicity, opsonization, poor 
biodistribution) of delivery systems for both in vitro and in vivo applications. I have used gold 
nanoparticles as a model platform to synthesize a family of nanoparticles with atomic level 
control of their surface properties and probe their interaction with biological systems (Figure 1.8). 
In the following chapters, I will give a detail description about the design and synthesis of these 
nanostructures and their use in recognition of proteins and cell surface for delivery applications.  
 
Figure 1.8. Dissertation overview. Schematic illustration of the biological applications of 
functionalized gold nanoparticles (AuNPs) described in this thesis. 
Development of new nanomaterials for biomedical applications requires thorough 
knowledge of its interaction with mammalian cells. In particular, how nanoparticles enter into the 
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cells and access cytosol is of utmost importance in the nanobiotechnology. Nanoparticles are 
taken up in the cells through a variety of mechanisms including phagocytosis, pinocytosis, and 
passive diffusion. Understanding the pathway involved in nanoparticle transport in the cells can 
aid in develop delivery vehicles targeting particular pathway in malignant cells over normal cells. 
Cationic nanoparticles are frequently used as transfection vectors for nucleic acids. Therefore, 
probing their mechanisms of entry in both malignant and non-malignant cells can help in design 
nanoparticles for selective delivery and minimal toxicity. In chapter 2, we have demonstrated that 
surface chemistry of cationic nanoparticles dictate their endocytic mechanisms in mammalian 
cells and mostly rely on dynamin, scavenger receptors, and caveolae/lipid raft-mediated 
pathways. Significantly, the existence of differential uptake pathways for the same NP in cancer 
and normal cells were observed that provides an opportunity to design nanocarriers of specific 
therapeutic action and reduced cytotoxicity. 
Toxicity of nanocarriers is a serious issue for any kind of delivery systems. Cationic 
nanoparticles are promising delivery vehicles and have been shown to possess differential 
transfection efficiency depending on their surface hydrophobicity. In Chapter 3, we have 
demonstrated that the mechanism of cytotoxicity of hydrophobic cationic nanoparticles. 
Hydrophobic nanoparticles showed higher cytotoxicity compared to the hydrophilic counterpart 
and concomitant reactive oxygen species generation in cancer cells. The genotoxicity is also 
observed for both hydrophilic and hydrophobic nanoparticles. This systematic study provides an 
understanding of nanoparticle interaction with mammalian cells that can be potentially harmful 
despite their high transfection capability. 
Any therapeutic nanocarriers are bound to come in contact with blood upon systemic 
administration. Blood cells and proteins are the first major entities nanoparticles interact in the 
body. Therefore, understanding the key parameter of nanoparticle surface properties that is not 
harmful for the red blood cells can mitigate severe life threatening consequences. In Chapter 4, 
we have demonstrated that hemolytic properties of nanoparticles linearly increase with the 
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surface hydrophobicity. However, the presence of plasma proteins (mimicking in vivo systems) 
masks the nanoparticle surface and rescues red blood cells from hemolytic activities. This 
parametric study also depicts a limit of nanoparticle surface hydrophobicity that can be safely 
used as injectable materials for in vivo applications. 
Evasion of mononuclear phagocytic system upon systemic administration is another 
critical aspect of designing delivery vehicles. Nanoparticles can bind serum proteins (opsonins) 
on its surface that can help macrophages to recognize and subsequent clearance from the 
circulation. Serum proteins, in general, mask the nanoparticle chemical identity and give them a 
unique biological identity depending on the surface functionality. In Chapter 5, we have 
demonstrated the interplay of protein adsorption and macrophage recognition of nanoparticle 
surface functionality. Using proteomics approach, detailed information of protein layer bound to 
surface engineered nanoparticles was investigated and found that nanoparticles bound to a variety 
of serum proteins including lipoproteins, immunoglobulins, acute phase proteins, coagulation 
proteins, etc that might dictate their fate in vivo. Importantly, the protein layer of each 
nanoparticle is unique depending on their surface functional groups. Hydrophobic nanoparticles 
demonstrated lower uptake in macrophage compared to hydrophilic nanoparticles and provide a 
design parameter to develop nanoparticles for in vivo applications. 
Binding of proteins at the surface of nanoparticles in the presence of biological fluids 
mask the surface properties of the particle and complicates the relationship between chemical 
functionality and biological effects. Unlike cationic nanoparticles, neutral particles do not bind 
proteins on their surface due to their strong interaction with water. In Chapter 6, we have 
designed a series of zwitterionic nanoparticles of variable hydrophobicity that do not adsorb 
proteins at moderate levels of serum protein and do not form hard coronas at physiological serum 
concentrations. These particles provide platforms to evaluate nanobiological behavior such as cell 
uptake and hemolysis dictated directly by chemical motifs at the nanoparticle surface. These 
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nanoparticles are also expected to be long circulating in blood, making them highly useful for 
studying nano-bio interaction in vivo. 
Stilumi-responsive nanoparticle provides a great platform to selectively enhanced uptake 
or release of therapeutics in response to internal triggers (pH, enzyme, etc.). Tumor 
microenvironment is known to be acidic (6-6.8) that makes it a highly promising stimulus for 
selective uptake of nanomaterials in tumor cells over normal cells. In chapter 7, we have 
developed a zwitterionic gold nanoparticle featuring a newly engineered pH-responsive 
alkoxyphenyl acylsulfonamide group. Due to its ligand structure, this nanoparticle is neutral at 
pH 7.4, eshew protein adsorption thereby evade immune system recognition and can become 
positively charged at tumor pH (< 6.5). The particle uptake and cytotoxicity increases 
dramatically over this pH range, while having high blood compatibility at blood pH. This smart 
design of nanomaterials can improve the blood half life of nanoparticles while gaining selective 
access to the tumor microenvironment. 
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CHAPTER 2 
SURFACE FUNCTIONALITY OF NANOPARTICLES DETERMINES 
CELLULAR UPTAKE MECHANISMS IN MAMMALIAN CELLS 
2.1. Introduction 
Nanoparticles (NPs) are key tools for biology and medicine, offering new strategies for 
biomedical applications including drug delivery1 and gene therapy.2 However, development of 
NPs with improved therapeutic efficacy requires a thorough knowledge of their interactions with 
cells to enhance delivery efficiency.3 In particular, the endocytic mechanisms by which NPs are 
transported into the cell control uptake and can potentially provide delivery strategies featuring 
enhanced targeting and minimal cytotoxicity.4 
 NPs can be uptaken by cells via two major mechanisms: phagocytosis and pinocytosis.5 
Phagocytosis occurs for particles larger than 0.5 µm in a limited number of mammalian cell types 
such as macrophages and monocytes. Pinocytosis is a far more general process that can be further 
classified into two subcategories: macropinocytosis and micropinocytosis. Macropinocytosis 
involves non-selective uptake of solute macromolecules of more than 0.2 µm diameter,6 whereas 
micropinocytosis (clathrin-mediated, caveolae/lipid raft-mediated, and clathrin/caveolae-
independent) occurs for smaller particles in all cell types (Scheme 1a).7 Given the size regime of 
NPs commonly used for therapeutic purposes (10-200 nm), NPs are expected to enter cells 
predominantly via micropinocytosis.  
Recent investigations have revealed that size,8 shape,9 and surface charge10 of NPs 
govern entry and subsequent cytosolic access of NPs into living cells.11 For example, cationic 
NPs have better cell membrane penetration efficiency than anionic NPs and are shown to enter 
mammalian cells via a different pinocytic mechanism.12 Likewise, particles with diameters of 
<200 nm were uptaken via clathrin-coated pits, whereas caveolae-mediated internalization 
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became predominant with increasing particle size.13 In addition to size and charge, NP surface 
functionality also plays an important role in terms of cellular uptake14 and eliciting cellular 
responses.15 Recently, Maysinger and coworkers have demonstrated that quantum dots bearing 
non-specific ligands on the surface were predominantly taken up by a lipid raft-mediated 
endocytosis in human kidney and liver cells.16 However, it is not clear how changes on the NP 
surface (e.g., hydrophobicity and aromaticity) affect cellular internalization processes. 
 
Figure 2.1. (a) Schematic representation of major pinocytic pathways of NPs in 
mammalian cells. (b) The gold NPs used in the present study. 
 
Herein, we report a mechanistic study of cellular uptake pathways of four cationic gold 
NPs (~2 nm core) featuring cationic head groups differing in structure and hydrophobicity 
(Figure 2.1). Experiments were performed in the presence of different endocytic inhibitors using 
healthy and cancerous cells to determine the specific entry route of the gold NP in human cells. 
The results indicate that the mode of cellular uptake is strongly dependent on the subtle changes 
of the NP surface monolayer. Importantly, these gold NPs possess different uptake mechanisms 
in normal and cancer cells, providing a potential strategy for selective delivery of drugs to tumor 
tissues.  
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2.2. Results and Discussion 
To probe the effect of NP surface functionality on the uptake mechanisms, we 
synthesized four structurally related gold NPs (NP1-NP4) that feature cationic ligands with 
diverse headgroups presented on a non-interacting scaffold (Figure 2.1b). All particles were 
synthesized from a single batch of pentanethiol-capped gold NPs (~2 nm core) via place 
exchange reactions17 and showed substantial peak broadening in 1H NMR spectra with no sign of 
free ligands after the reaction. As expected, all of the particles have similar hydrodynamic 
diameters and positive zeta potentials. We studied NP uptake in two human cell lines: HeLa (a 
cervical carcinoma cell line) and MCF10A (a non-tumorigenic mammary epithelial cell line), 
providing a platform to examine the uptake mechanisms of gold NPs in both malignant (HeLa) 
and non-malignant cells (MCF10A).  
 
Figure 2.2. ICP-MS measurements of intracellular uptake of NP1-NP4 in (a) HeLa and (b) 
MCF10A cells after 1 h of NP incubation in serum free media. Error bars represent standard 
deviation. 
NP uptake in cells was quantified using inductively coupled plasma mass spectrometry 
(ICP-MS).18 After 1 h incubation of HeLa and MCF10A cells with NP1-NP4 (100 nM each) in 
serum free media, the cells were analyzed for intracellular gold content. The uptake amount 
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increases from NP1 to NP4 in HeLa cells (Figure 2.2a) while remained similar in the case of 
MCF10A cells (Figure 2.2b). No significant cytotoxicity was observed for any of the NPs (100 
nM each) in either cell type (Figure 2.3). 
Next, we investigated the effect of endocytic inhibitors on the cellular uptake 
mechanisms for the NPs. For all experiments, HeLa or MCF10A cells were pretreated with an 
inhibitor for 1 h followed by 1 h of incubation with the NPs in the presence of the inhibitor. 
Experiments were performed in serum free condition to exclude the effect of protein adsorption 
on NP surfaces that can potentially alter the endocytic pathways.19 We focused first on the three 
major pinocytic pathways of cellular entry: macropinocytosis, clathrin-dependent, and 
caveolae/lipid raft-dependent micropinocytosis. No uptake inhibition was observed in either cell 
type for NP1-NP4 using wortmannin (WMN) (Figure 2.3a), an inhibitor that blocks the action of 
phosphoinositide 3-kinase, a key regulator in macropinocytosis.20 This determination was further 
confirmed using sodium azide (NaN3)/2-deoxyglucose (DOG), a system that depletes cellular 
ATP levels required for macropinocytosis (Figure 2.6). 21   
 
Figure 2.3. Cytotoxicity of NP1-NP4 (100 nM each) in (a) HeLa and (b) MCF10A cells after 1 
hour, determined by alamar blue assay. 
Membrane invagination during micropinocytosis requires microtubule and actin filament 
reorganization,22 a process observed in NP uptake.23 To evaluate the effect of cytoskeletal 
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rearrangement on NP uptake, we used two inhibitors: cytochalasin D (CytD)24 and nocodazole25 
that disrupt F-actin polymerization and microtubule formation, respectively. In the case of CytD 
treated cells, the uptake of the NPs remained unaffected in both cell types except for NP3 that 
showed ~20 % inhibition in HeLa cells relative to the control (Figure 2.4b). Likewise, treatment 
with nocodazole did not show any significant inhibition for any of the particles in either HeLa or 
MCF10A cells (Figure 2.6), demonstrating cytoskeletal rearrangement is not critical for uptake of 
monolayer-protected NPs in either cell type. 
 
Figure 2.4. Uptake % of NP1-NP4 (compared to the positive controls) in the presence of different 
endocytic inhibitors in HeLa and MCF10A cells, (a) wortmannin (WMN), (b) cytochalasin D 
(CytD), (c) chlorpromazine (CPM), (d) methyl-β-cyclodextrin (MBCD). Error bars represent 
standard deviation. *p<0.05, **p<0.01 compared to the control. 
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Previous reports have demonstrated that cationic NPs (diameters ~90 nm) can enter HeLa 
cells via clathrin-dependent pathways.26 However, we did not observe any strong inhibition in 
either HeLa or MCF10A cells using chlorpromazine (CPM),27 an inhibitor of clathrin-mediated 
endocytosis (Figure 2.4c). In contrast, strong uptake inhibition (~50 %) was observed for NP2 in 
the cells pretreated with the cholesterol-depletion agent methyl-β-cyclodextrin (MBCD),28 
demonstrating the possible involvement of caveolae/lipid raft-mediated endocytosis for NP2 in 
HeLa cells (Figure 2.4d). In MCF10A cells, however, only NP4 showed significant uptake 
inhibition using MBCD. Therefore, subtle changes in the NP monolayer can switch the endocytic 
pathways in malignant and non-malignant cells, offering the potential for selective targeting 
strategies.29 The other particles studied did not show any significant reduction of cellular uptake 
in the presence of any of the above inhibitors, indicating that the broader classes of endocytosis 
including macropinocytosis and clathrin-dependent endocytosis are not the major routes of entry 
of these monolayer-protected gold NPs into HeLa and MCF10A cells. 
Recently, the dynamin-dependent endocytosis pathway has been extensively studied as a 
possible clathrin-independent transport mechanism into the cell.30 We observed a significant 
inhibition of NP2 uptake (~60 %) in HeLa cells using dynasore (Figure 2.5a), an endocytic 
inhibitor that interferes with the dynamin-dependent pathways by blocking dynamin-GTPase.31 
Therefore, NP2 uptake is governed by both caveolae/lipid raft (Figure 2.4d) and dynamin-
dependent pathways, a distinctly different feature from the other NPs studied. Surprisingly, in the 
case of MCF10A cells, uptake of all NPs was strongly inhibited by dynasore (Figure 2.5a) with 
NP2 being the most strongly inhibited (~80 %). Therefore, the dynamin-dependent pathway plays 
a key role in NP1-NP4 endocytosis in MCF10A cells, a striking difference from HeLa cells where 
only NP2 showed significant inhibition.  
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Figure 2.5. Uptake % of NP1-NP4 (compared to the positive controls) in HeLa and MCF10A 
cells in the presence of (a) dynasore and (b) poly I. Error bars represent standard deviation. 
*p<0.05,**p<0.01, ***p<0.001 compared to the control. 
To investigate whether a more specific endocytic pathway is involved for the other NPs, 
we studied the involvement of scavenger receptors and membrane-bound G-protein coupled 
receptor (GPCR)32-mediated uptake pathways in both of the cell types. Scavenger receptors bind 
to a variety of ligands including low density lipoproteins and polysaccharides33 and  have been 
shown to be involved in gold NP uptake.34 Poly I, a well-known inhibitor of scavenger 
receptors,35 inhibited NP1 and NP3 uptake in both HeLa and MCF10A cells (Figure 2.5b), 
confirming the involvement of scavenger receptors for NP uptake in different mammalian cells. 
Significant uptake inhibition was observed for NP2 in MCF10A cells in the presence of poly I, 
however, this effect was not pronounced in HeLa cells.  Conversely, Gαi-protein (sub-family of 
GPCR) inhibitor pertussis toxin (PTX)36 and phospholipase C inhibitor U-7312237 did not show 
any reduction in uptake for any of the particles (Figure 2.6), demonstrating that GPCRs play no 
role in NP1-NP4 uptake in HeLa and MCF10A cells.  
 
 
 
30 
 
Table 2.1. Summary of uptake inhibition of NPs in presence of endocytic inhibitors 
 
Taken together, the broader classes of endocytic pathways including macropinocytosis 
and clathrin-mediated endocytosis were not the predominant uptake mechanisms for NP1-NP4 in 
both malignant and non-malignant cells. However, highly regulated uptake was observed via 
caveolae and dynamin-dependent micropinocytosis as well as through specific membrane-bound 
receptors in both of the cell types. For example, NP1 and NP3 showed scavenger receptor-
mediated uptake while NP2 showed both caveolae and dynamin-dependent uptake in HeLa cells, 
demonstrating multifaceted internalization mechanisms of NPs into cells.38 NP4 did not show 
strong uptake inhibition in HeLa cells for any of the classes of inhibitors tested, demonstrating the 
role of clathrin-independent/dynamin-independent mechanisms in mammalian cells.30 In 
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MCF10A cells, both dynamin and scavenger receptor-mediated uptake was predominant for all of 
the particles except NP4 that also showed caveolae/lipid raft-mediated uptake (Table 2.1). 
2.3. Conclusions 
We have demonstrated that the mechanisms of small (~10 nm hydrodynamic diameter) 
cationic gold NP uptake in both malignant and non-malignant cells are strongly dependent on the 
gold NP monolayer structures and mostly rely on dynamin, scavenger receptors, and 
caveolae/lipid raft-mediated pathways. Significantly, the existence of differential uptake 
pathways for the same NP in cancer and normal cells provides an opportunity to design 
nanocarriers of specific therapeutic action and reduced cytotoxicity. Taken together, these studies 
indicate the importance of NP surface monolayer structures in endocytic pathways and signify the 
role of particle design in nanomedicine. 
2.4. Experimental Section 
Synthesis of NP1-NP4: 1-Pentanethiol capped gold nanoparticles (d=~2 nm) were 
synthesized according to Brust-Schiffrin method.39 A place exchange reaction40 was performed 
by dissolving corresponding thiol ligands and pentanethiol capped gold nanoparticles in 
dichloromethane (DCM) and stirring for 3 days in room temperature under argon atmosphere. 
The solvent was removed under reduced pressure and the resulting precipitate was dissolved in 
distilled water and dialyzed for 2 days (membrane molecular cut-off =10000) to remove excess 
ligands, acetic acid and other salts present in the nanoparticle solution. After dialysis, the particle 
was lyophilized to yield a solid brownish product. The particles are then redispersed in deionized 
water. 1H NMR-spectra in D2O showed substantial broadening of the proton peaks with no sign 
of free ligands. 
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Cell culture: HeLa cells were grown in low glucose Dulbecco’s Modified Eagle’s 
Medium (GIBCO, Catalog# 10567) supplemented with 10% fetal bovine serum (Thermo 
Scientific, SH3007103) and 1% antibiotics (Cellgro, 30-004-CI). The cells were maintained in the 
above media and subcultured once every four days. MCF10A cells were grown in mammary 
epithelium growth medium (Lonza, CC-3051A) supplemented with bovine pituitary extract 
(Lonza, CC-4009). Media were replaced every two days and cells were subcultured every seven 
days. 
NP uptake and inhibition studies: HeLa or MCF10A cells were seeded in a 48 well 
plate at a density of ~2×104 cells/well 24 h prior to the experiment. On the following day, cells 
were washed one time with phosphate buffered saline (PBS) and incubated with following 
endocytic inhibitors in serum free media for 1 h at 37 ˚C: cytochalasin D (10 µg/mL), methyl-β-
cyclodextrin (5 mg/mL), nocodazole (10 µg/mL), 3 mg/mL NaN3/50 mM 2-deoxyglucose, 
wortmannin (100 ng/mL), pertussis toxin (100 ng/mL), U-73122 (4 µg/mL), polyinosinic acid (10 
µg/mL), chlorpromazine (10 µg/mL) and dynasore (80 µM). The concentrations of the inhibitors 
were used as described in previous reports.41 After 1 h, media were replaced with fresh media 
containing the inhibitors with NPs (100 nM) and further incubated for 1 h at 37 ˚C. Untreated 
cells and cells treated with only NPs (no inhibitor) were used as negative and positive controls, 
respectively. After incubation, cells were washed three times with PBS and lysis buffer was 
added to each well. All lysed cell samples were then further processed for ICP-MS analysis (vide 
infra) to determine the intracellular amount of gold. All inhibitors were purchased from Sigma 
except for dynasore, chlorpromazine, and pertusis toxin that were obtained from Fisher Scientific. 
Particle uptake (%) was calculated based on the following equation: 
 
NP uptake (%) = (NP uptake in presence of inhibitors/NP uptake in absence of inhibitors) 
× 100 
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Sample preparation for ICP-MS and ICP-MS instrumentation: After cellular uptake, 
the lysed cells were digested with 0.5 mL of fresh aqua regia (highly corrosive and must be used 
with extreme caution!) for 10 minutes. The digested samples were diluted to 10 mL with de-
ionized water. A series of gold standard solutions (20, 10, 5, 2, 1, 0.5, 0.2, and 0 ppb) were 
prepared before each experiment. Each gold standard solution also contained 5% aqua regia. The 
gold standard solutions and cellular uptake sample solutions were measured on an Elan 6100 ICP 
mass spectrometer (PerkinElmer SCIEX, Waltham, MA). The instrument was operated with 1550 
W RF power and the nebulizer Ar flow rate was optimized at 0.96 L/min. 
Cytotoxicity of NPs in HeLa and MCF10A cells: The cell viability was determined by 
alamar blue assay according to manufacturer protocol (Invitrogen Biosource, USA). HeLa or 
MCF10A cells (~15000 cells/well) were seeded in a 96-well plate 24 hours prior to the 
experiment. On the following day, the old media was aspirated and the cells were washed with 
phosphate buffered saline (PBS) for one time. NP1-NP4 (100 nM each) were then incubated with 
the cells in serum free medium for 1 hour at 37 ˚C. After the incubation period, the cells were 
washed three times with PBS and 220 µL of 10 % alamar blue solution in serum containing 
media was added to each well and cells were further incubated at 37 ˚C for 4 hours. After 4 hours, 
200 µL of solution from each well were taken out and loaded in a 96- well black microplate. Red 
fluorescence, resulting from the reduction of the alamar blue solution by viable cells was 
monitored (Ex: 560 nm, Em: 590 nm) on a SpectroMax M2 microplate reader (Molecular 
Device). Viability (%) of NP-treated cells was calculated taking untreated cells as 100 % viable. 
Each experiment was done in triplicate. 
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2.5. Supplementary Information 
 
Figure 2.6. % Uptake of NP1-NP4 (compared to positive controls) in both HeLa and MCF10A 
cells in the presence of endocytic inhibitors (a) NaN3/2-deoxyglucose, (b) pertussis toxin (PTX), 
(c) Nocodazole, (d) U-73122. *p<0.05 compared to control. 
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CHAPTER 3 
THE ROLE OF SURFACE FUNCTIONALITY ON ACUTE CYTOTOXICITY, 
ROS GENERATION AND DNA DAMAGE BY CATIONIC GOLD 
NANOPARTICLES 
3.1. Introduction 
Gold nanoparticles (AuNPs) are promising materials for biomedical applications1,2 due to 
their tunable surface properties 3 and extraordinary stability.4 Additionally, the inert core material 
reduces the potential for toxicity issues arising from particle degradation.5 The size regime and 
concomitant geometrical outcomes including high degree of curvature, however, generates the 
potential for toxicity.6,7  Generally, the toxicity of AuNPs depends on size, shape, the degree to 
which they aggregate, and their surface properties.8 Recently, several studies on the short-term 
cytotoxicity of AuNPs9 and quantum dots10 have focused on size,11,12 shape,13,14 and charge.15  To 
date, however, issues such as ligand hydrophobicity have not been systematically explored. 
In addition to acute toxicity arising from lysis and other disruptive events, DNA damage 
(genotoxicity) is an important issue in the application of nanomaterials. DNA damage provides 
both a useful strategy for anti-cancer drugs as well as a potential challenge for the design of non-
cytotoxic therapeutics. Recently, El-Sayed and coworkers has shown that AuNPs with nuclear 
targeting motifs elicit significant damage of DNA and concomitant programmed cell death.16 This 
outcome mirrors the behavior of anticancer drugs such as cisplatin and analogs.17 As such, 
AuNPs can be envisioned as therapeutic agents in their own right as well serving as carriers for 
other drugs and biomolecules.18 Taken together, an in-depth understanding of how NPs interact 
with cell surfaces and cellular organelles is central to their applications in biomedicine. 19 
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Figure 3.1. A series of AuNPs used in this study and a proposed mechanism of DNA damage 
determined by comet assay. 
Recently, several reports have described varying degrees of transfection efficiency of 
cationic lipids by increasing the chain length and hydrophobicity.20 Hence, to examine the effect 
of surface hydrophobicity on acute and long-term nanoparticle cytotoxicity, we have synthesized 
a series of 2 nm core AuNPs that feature an quaternary ammonium functionality with a 
systematically varied (C1-C6) hydrophobic alkyl tail (Figure 3.1). We have quantified the acute 
cytotoxicity of these AuNPs through mitochondrial activity assay, and the potential for long-term 
toxicity through quantification of reactive oxygen species (ROS) generation and DNA damage. 
Results are strongly dependent upon side chain structure, with greater acute toxicity and 
decreased DNA damage observed with increasing hydrophobicity.  Significantly, these AuNPs 
can generate significant amounts of reactive oxygen species (ROS) that oxidatively damage DNA 
at concentrations that do not affect mitochondrial activity.  These results suggest that caution is 
needed in the use of small AuNPs as carriers. Importantly, these results indicate the potential 
utility of these systems as cytotoxic therapeutic agents for cancer therapy. 
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3.2. Results and Discussion 
The required AuNPs were synthesized via place exchange21 of pentanethiol capped 
AuNPs (~2 nm) fabricated by Brust-Schiffrin reduction method.22 Acute toxicity of the 
nanoparticles was determined through the alamar blue assay, a method based on mitochondrial 
activity. HeLa cells were treated with AuNPs dispersed in culture media with the concentrations 
ranging from 0-10 µΜ and incubated for 24 h. As shown in Figure 3.2, cellular viability 
decreases with increasing alkyl chain length, i.e. AuNP 1 is the least toxic (IC50 = 6 µM) while 
AuNP 4 is the most toxic (IC50 = 0.71 µM).                               
 
Figure 3.2. Cytotoxicity of AuNP 1-4 in HeLa cells determined by alamar blue assay and IC50 of 
particular AuNPs. The box represents the concentration range used in the ROS generation and 
DNA damage study. 
In general, nanomaterials that retain >80% cell viability are considered safe for use in 
biological applications.23 We next determined whether nanoparticles in this concentration range 
are capable of generating endogenous ROS and further causing DNA damage. As cellular uptake 
of these nanomaterials depends upon surface functionality,24,25  we first used ICP-MS to 
42 
 
determine the extracellular concentrations of nanoparticle required to obtain a constant 
intracellular AuNP concentration (214 ng/well, Figure 3.3a). The calculated concentrations 
yielding 214 ng/well of intracellular gold were 100, 123, 148, and 165 nM for AuNP 1 to AuNP 
4, respectively, and were in the regime where treatment with all particles provided 100% 
viability.  
 
Figure 3.3. a) Uptake of AuNP1-4 in HeLa cells b) ROS in HeLa cells determined by the 
oxidation of H2DCFDA dye. The intracellular gold in each AuNPs was 214 ng/well. The controls 
were cells alone and cells treated with exogenous H2O2 (0.3% v/v). The data were statistically 
analyzed and significant ROS level difference was found between AuNP 1 and AuNP 4 (t=12.57, 
p=0.0002). 
Endogenous ROS production was quantified using 2',7'-dichlorodihydrofluorescein 
diacetate (H2DCFDA).26 ROS species convert non-fluorescent H2DCFDA to its fluorescent 2',7'-
dichlorofluorescein (DCF) that can be quantified using a micro plate reader. Again, HeLa cells 
were treated with AuNPs dispersed in the cell culture media and incubated for 24 h. From Figure 
3.3 it can be seen that the production of ROS was dependent on the AuNPs functionalization. The 
results indicate that increasing hydrophobicity increases ROS production, a result that mirrors 
mitochondrial activity albeit at much lower concentrations.  
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Figure 3.4.  a) Tail Length of AuNP 1-4 from the comet assay b) % Tail DNA of AuNP 1-4 from 
the comet assay. Statistical analysis by ANOVA and post hoc t-tests with Bonferoni Correction for 
multiple comparisons revealed all of the nanoparticles caused significant DNA damage compared 
to control. (p<0.001) 
Having established that hydrophobicity plays an important role in the generation of ROS 
and hence potential genotoxicity, we next explored the effect of particle hydrophobicity on DNA 
damage. DNA damage was quantified through the single cell gel electrophoresis, using the comet 
assay.27 This technique provides a versatile and sensitive method to detect DNA damage.  As 
with the ROS studies, the cells were incubated with AuNPs for 24 h. The cells were then 
trypsinized, embedded in agarose gel, and then lysed prior to performing gel electrophoresis. The 
DNA embedded in the gels was stained with SYBR Green dye and imaged by fluorescence 
microscopy (40X magnification) (Figure 3.5). The data were analyzed by Komet software. We 
observed that all four AuNPs significantly damage DNA in comparison to the control, as 
indicated by both  and Tail Length (Figure 3.4a) and % Tail DNA (Figure 3.4b). Interestingly, 
AuNP 1 caused significantly greater DNA damage than the rest of the AuNPs, contrasting with 
data derived from the mitochondrial activity (Figure 3.2) and ROS generation assay (Figure 3.3b). 
In addition, the percent of damaged cells was defined as those with values of % Tail 
DNA and Tail Length greater than two standard deviations above the mean of the control group 
values. Again, AuNP 1 resulted in the greatest percent of damaged cells (Figure 3.5). The degree 
of DNA damage is comparable to mercaptoundecanoic acid-functionalized quantum dots (tail 
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length~ 76±3.52 μm, @200 μg/mL)10 Notably, AuNP 1 causes DNA damage similar to cisplatin 
(79.7±8% DNA in Tail) when administered to cells at concentrations that yield 75% cell 
viability.28   
3.3. Conclusions 
We have determined that both the acute cytotoxicity and genotoxicity of positively 
charged AuNPs depend on the hydrophobicity of the ligands attached. Increasing the 
hydrophobicity of the particles increased their cytotoxicity. Increasing hydrophobicity likewise 
increased ROS production, even at AuNP concentrations where 100% cell viability was observed. 
Interestingly, DNA damage decreased with increasing particle hydrophobicity. In literature, 
conflicting cytotoxicity and DNA damage result has been reported between structurally similar 
complexes.28 In addition, cells have in vivo mechanisms that maintain homeostasis.29 Moreover, 
treatment with AuNPs induces the endogenous ROS production. This oxidative stress 
environment could initiate the autophagic process,30 which can destroy foreign molecules to 
avoid cell death. This process may contribute cell survival in an oxidative environment of NPs. 
Therefore, AuNP 4 which produces more ROS, can be presumably degraded due to autophagy 
and will be less available to damage DNA. Taken together, these studies indicate that AuNPs can 
be employed not only as carriers but also as potential therapeutics that exploit their capability to 
elicit cell function and generate cytotoxic and genotoxic responses.  
3.4. Experimental Section 
Cell culture: HeLa cells were cultured at 37°C under a humidified atmosphere of 5% 
CO2. The cells were grown in low glucose Dulbecco’s Modified Eagle’s Medium (DMEM, 4.0 
g/L glucose) containing 10% fetal bovine serum and 1% antibiotics (100 U/ml penicillin and 100 
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μg/ml streptomycin). The cells were maintained in the above media and subcultured once every 
four days. 
Alamar blue assay: The cell viability was evaluated by using an alamar blue assay 
according to the manufacturer’s protocol (Invitrogen Biosource, USA). In a typical experiment, 
cells were seeded at 3000 cells/well in a 96 well-plate 24 h prior to the experiment. On the 
following day, the old media was aspirated and cells were washed one time with cold PBS before 
putting the different concentrations of AuNP 1, AuNP 2, AuNP 3 and AuNP 4 ranging from 0-10 
µM dispersed in the pre-warmed serum-containing media. The cells were again incubated 24 h at 
37°C under a humidified atmosphere of 5% CO2.  On the next day, after thoroughly washing the 
cells three times with PBS buffer, the cells were treated with 220 µL of 10% alamar blue in 
serum-containing media. Subsequently, the cells were incubated at 37°C under a humidified 
atmosphere of 5% CO2 for 3 h. After 3 h of incubation, 200 µL of solution from each wells was 
taken out and placed in a 96-well black microplate. Red fluorescence, resulting from the 
reduction of alamar blue solution, was valued (excitation/emission: 535 nm/590 nm) on a 
SpectroMax M5 microplate reader (Molecular Device) to determine the cellular viability. Each 
experiment was done in triplicate. 
Endogenous reactive oxygen species (ROS): The ROS was determined through a 
microplate reader. HeLa cells were plated into a 24-well plate (20K /well) for 24 h prior the 
experiment. On the following day, cells were treated with AuNPs with the concentration of 100, 
123, 148, and 165 nM for AuNP 1 to AuNP 4, respectively. As a positive control experiment, 
cells were treated with 0.3% H2O2 suspended in culture media and incubate for 30 min at 37°C 
before performing the assay. After 24 h incubation, cells were wash with PBS 3 times and were 
subsequently treated with 2',7'-dichlorodihydrofluorescein diacetate, H2DCFDA (Molecular 
Probes/ Invitrogen) (250 mL, 5 µM/well). Experiments were done in triplicate. After incubating 
for 30 min, the cells were washed by PBS and lysed with cell lysis buffer (Gene Therapy 
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Systems). 200 µL of solution from each well was transferred to a 96-well black microplate. 
Fluorescence intensity, resulting from the oxidation of dye, was valued (excitation/emission: 488 
nm/520 nm) on a SpectroMax M5 microplate reader (Molecular Device) to determine the level of 
ROS. The level of ROS production by AuNPs was compared using a one way ANOVA and post 
hoc t-tests with a Bonferoni Correction for multiple comparisons. All four AuNPs resulted in a 
significant increase in ROS levels (ANOVA; F=45.08; df=5, 11). Moreover, ROS produced by 
AuNP 1 was significantly less than AuNP 2 (p=0.006), AuNP 3 (p=0.005), & AuNP 4 
(p=0.0001). 
Comet assay: For the comet assay, the HeLa cells were maintained as mentioned above. 
HeLa cells (20K cells/well) were plated in a 24-well plate for 24 h prior to performing the 
experiment. On the day of the experiment, cells were washed using cold PBS once. Thereafter, 
AuNPs were dispersed in pre-warmed serum-containing media with the final concentration 
determined according to ROS experiments.  Cells were treated with AuNP solution and kept in 
cell culture incubator for 24 h. For the comet assay, cells were washed in PBS three times and 
trypsinized by trypsin EDTA 1X (MediaTech, Inc, USA). Cells were collected by centrifugation 
at 1000 rpm, 5 min. After centrifugation, cells were dispersed in PBS and embedded in 1% low 
melting point agarose (Agarose Type I-B, Sigma Aldrich). The agarose gel was transferred to 
CometSlideTM HT (Trevigen, USA) and kept in 4°C refrigerator for 10 min.  Slides were placed 
in a cold lysis solution (2.5 M NaCl, 80 mM Na2-EDTA, 1 mM Tris-HCl, and 1% Triton X-100, 
pH 10) and kept at 4°C in the dark for 24 h. Electrophoresis was performed in 0.3 M NaOH, 0.5 
mM Na2-EDTA, and pH 13 for 35 min at 20 V, 300 mA.  The slides were then neutralized and 
stained with SYBR Green dye (Invitrogen, USA).  The comet images were pictured for 34, 52, 
59, 76 nuclei for AuNP 1-4, respectively using a fluorescence microscope (40X magnification, 
Nikon E600 microscope stand) with a green filter.  The data were analyzed through Komet 
software. One-way analysis of variance revealed significant effects of treatment group for both 
tail length (F=10.33; df=243, 4; P<0.001) and % tail DNA (F=12.18; df=242, 4; P<0.001). Post 
47 
 
hoc t-tests with Bonferoni Correction for multiple comparisons demonstrated that all of the 
nanoparticles caused significant DNA damage.  
3.5. Supplementary Information 
 
Figure 3.5.Optical images of comet assay from each treatment. a) cell alone, b) cell alone, 
c)AuNP 1, d) AuNP 2, e) AuNP 3, f) AuNP 4. 
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CHAPTER 4 
SERUM PROTEINS SUPPRESS THE HEMOLYTIC ACTIVITY OF 
HYDROPHILIC AND HYDROPHOBIC NANOPARTICLES 
4.1. Introduction 
Intravascular rupture of red blood cells (RBCs) upon systemic administration of 
therapeutic NPs can elevate plasma level of cell-free hemoglobin leading to endothelial cell 
dysfunction and vascular thrombosis.1  This acute hemolysis can further cause hemolytic anemia 
that result in multiple organ failure2 and death.3 Several reports have recently demonstrated the 
hemolytic activities of therapeutic NPs both in vitro4 and in vivo,5 indicating potential adverse 
side-effects of NPs that can limit applications in nanomedicine. However, a lack of parametric 
study in vitro on NP hemolytic behavior makes their interaction profile difficult to predict in vivo. 
Surface functionality of NPs is central to their effective use in therapeutic applications, 
imparting functional properties6 and dictating their circulation profile in the blood stream.7 
However, in contrast to small molecule therapeutics the formation of a protein corona on the NP 
surface during blood circulation8 alters surface chemical behavior of NPs and defines its 
physiological responses.9  This interplay of NP surface functionality and the protein corona 
formed in situ would be expected to dictate the overall interaction of NPs with RBCs, regulating 
the hemolytic behavior of NPs. To date, however, there is no clear understanding how changes on 
NP surfaces coupled with the formation of protein corona control the hemolytic properties of 
NPs.10  
Herein, we report the role of NP surface functionality on hemolytic activity in the 
presence and absence of plasma proteins. To this end, we have synthesized a class of cationic 
gold NPs of same core size (~2 nm), differing in their surface hydrophobicity (Figure 4.1). These 
NPs showed a direct increase in hemolytic activity with the increase of surface hydrophobicity in 
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the absence of plasma proteins. Significantly, the presence of protein corona dramatically altered 
the hemolytic activity of these NPs; hemolysis was only observed in the most hydrophobic of 
surface coverage. These studies demonstrate the importance of serum proteins in moderating 
hemolytic activity, expanding the range of particle surfaces that can be employed without 
hemolytic consequences. 
 
Figure 4.1. The structure of the NPs used to probe haemolytic activity of functionalized AuNPs. 
logP denotes the relative hydrophobic indices of R groups. 
4.2. Results and Discussion 
The NP surface hydrophobicity has a critical role in the cellular uptake,11 toxicity,12 and 
immune responses13 of nanomaterials. To understand the role of NP surface hydrophobicity on 
the blood compatibility, a family of nine cationic NPs was synthesized systematically changing 
the degree of surface hydrophobicity by the use of specific chemical groups (Figure 4.1).14  This 
chemical approach allows us to control the nature of the monolayer (nanoparticle surface), while 
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maintaining the other physico-chemical properties (e.g. size and surface charge) constant. Using 
this system, the NP properties can be translated into numerical descriptors, as demonstrated 
previously by interfacial tension experiments.15 As such, the logP of the headgroups (R groups, 
Figure 4.1) was employed to describe the relative hydrophobic nature of the NP surface. 
In prior studies, we have demonstrated that cationic NPs showed significantly higher 
hemolysis compared to anionic counterpart.16  To this end, NPs with different surface charge e.g. 
cationic, anionic, neutral, and zwitterionic (500 nM each) were incubated with RBCs for 30 min 
and the absorbance of released hemoglobin from the hemolyzed RBCs were measured at 570 
nm.17 We observed a significantly higher hemolytic activity of cationic NPs compared to NPs 
with other surface charges (anionic, neutral, and zwitterionic) (Figure 4.2), corroborating 
previous reports.18   
 
Figure 4.2. The effect of the nanoparticle surface charge on hemolysis. a) Physical observation of 
the supernatant after nanoparticle addition and centrifugation. b) Values of hemolysis relative to 
positive control. Experiments were performed by triplicate. Extreme left and right values are 
negative control (no nanoparticles) and positive control (water). 
  The role of NP surface hydrophobicity on hemolytic behavior was established 
incubating NP1-NP9 (500 nM each) with RBCs as mentioned above. A direct increase in 
hemolytic activity was observed for NP1-NP9 with the increase of hydrophobicity (Figure 4.3), 
demonstrating the role of NP surface hydrophobicity on the hemolysis. Significantly, NPs with 
similar headgroup logP but different chemical functionalities e.g. NP2 and NP3 demonstrated 
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different degree of hemolysis (~4.5% and 13.5% respectively), evidencing the role of specific 
functional groups on the observed hemolytic behavior.  
 
Figure 4.3. Hemolytic activities of NP1-NP9 (500 nM each) in the absence of plasma proteins. 
RBCs were incubated with NPs for 30 min in PBS at 37 ˚C and the mixture was centrifuged to 
detect the cell-free hemoglobin in the supernatant. % Hemolysis was calculated using water as the 
positive control. Error bars represent standard deviation (n=3). 
The dose-dependent hemolytic behavior of these NPs was investigated exposing RBCs to 
a range of concentrations of NPs from 8 nM to 500 nM. As shown in Figure 4.4, a dose-
dependent increase of hemolysis was observed for all NPs. NP1-NP3 did not show significant 
hemolysis at the highest concentration tested (500 nM), demonstrating biocompatibility of these 
particles towards RBCs. Significantly, a sigmoidal dose-response curve was observed for more 
hydrophobic NPs, demonstrating the co-operative nature of hemolytic process for these NPs.19  
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This result demonstrated that the subtle changes on NP surfaces can modulate the interaction 
profile with RBCs, leading to different hemolytic profile. 
 
Figure 4.4. Dose-dependent hemolytic activity of NP1-NP9 in the absence of plasma proteins. % 
Hemolysis was calculated using water as the positive control. Error bars represent standard 
deviation (n=3). 
Binding of plasma proteins on NP can mask the chemical nature of the NP surface, 
altering their activity in vivo.20  The hemolytic activity of NP1-NP9 was further studied in the 
presence of 55% of plasma protein, a condition NPs will meet while administered in the blood 
stream. NPs were pre-incubated with 55% plasma in PBS for 30 min and then added to the RBCs. 
The pre-incubation time was chosen to have certainty of the protein absorption, although protein 
coronas form within minutes after NP exposure.21 Following incubation with RBCs, the 
absorbance of the supernatant was measured at 570 nm to monitor the extent of hemolysis (vide 
supra). In presence of plasma, little to no hemolysis was observed for NP1-NP6 (Figure 4.5). 
Significantly, NP6 that showed ~70% hemolysis in the absence of plasma protein, demonstrated 
no hemolytic activity in the presence of plasma even after 24 hr, a striking example of the effect 
of protein corona formation on NP surface. Likewise, NP7-NP9 demonstrated significant 
decrease in hemolytic activities (more than 20-fold) in presence of plasma within 30 minutes. 
However, NP7-NP9 still showed ~5% hemolysis within 30 min, demonstrating hemolytic 
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potential of these NPs even in the presence of plasma proteins. This behavior was more 
pronounced after 24 hr where NP7 and NP9 showed severe hemolysis (Figure 4.5). Significantly, 
NP7 and NP8 showed different hemolytic activities after 24 hr albeit their similar headgroup 
hydrophobicity, presumably due to the NP aggregation in high protein concentration and/or 
selective amount of protein adsorption on NP surface. Nonetheless, this study signifies the 
interplay of the chemical functionalities on NP surface and the protein corona formed in situ, 
making NPs ‘silent’ towards hemolytic consequences. However, NPs with high degree of surface 
hydrophobicity (headgroup logP > 4) demonstrated severe hemolysis, providing a limit of the NP 
surface hydrophobicities tested in this study.  
 
Figure 4.5. Hemolytic activities of NP1-NP9 (500 nM each) in the presence of plasma proteins. 
NPs were pre-incubated with 55% of plasma in PBS following incubation with RBCs for 30 min 
and 24 hr at 37 ˚C. The mixture was centrifuged to detect the cell-free hemoglobin in the 
supernatant. % Hemolysis was calculated using water as positive control. Error bars represent 
standard deviation (n=3). 
4.3. Conclusions 
In summary, we have demonstrated the critical synergy between NP surface chemical 
functionalities and the protein corona, leading to dramatically attenuated hemolytic behaviour of 
NPs. In the absence of plasma proteins, a linear hemolytic profile was observed with increasing 
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NP surface hydrophobicity. Significantly, the presence of plasma protein passivated both 
hydrophilic and hydrophobic NP surfaces leading to no hemolysis within 30 min. NPs with the 
highest degrees of hydrophobicity (headgroup logP>4), however, maintained their hemolytic 
properties (24 hr) presumably due to aggregation in the presence of plasma proteins. This study 
signifies the protective role of protein corona for improved blood compatibility and provides 
extended design parameters for therapeutic nanomaterials without toxic consequences.  
4.4. Experimental Section 
Nanoparticle synthesis: Gold nanoparticles cores (d~2nm) stabilized with a monolayer 
of 1-pentanethiol were synthesized following the Brust-Schiffrin methodology.22 All the 
impurities were removed according to our own protocol to certify that the phase-transfer catalyst 
do not interfere in the biological tests.23 To functionalize the cores with the desired ligands, a 
Murray place-exchange reaction24 was performed by dissolving the thiolated ligand in dry DCM 
with the gold cores, stirring for 3 days at room temperature (5:1 w/w ratio of ligand/gold cores). 
DCM was then evaporated under reduced pressure and the residue was dissolved in distilled 
water. Dialysis was performed during 5 days (membrane MWCO = 10,000) to remove excess of 
ligand and salts remaining in the nanoparticle solution. After dialysis, the particles were 
lyophilized and dissolved in deionized MQ water. Nanoparticle concentration was obtained 
following the reported procedure.25 The ligands were synthesized according to our previous 
reports.26 
Hemolysis assay in the absence of plasma proteins: Citrate-stabilized human whole 
blood (pooled, mixed gender) was purchased from Bioreclamation LLC, NY and processed as 
soon as received. 10 mL of phosphate buffered saline (PBS) was added to the blood and 
centrifuged at 5000 r.pm. for 5 minutes. The supernant was carefully discarded and the red blood 
cells (RBCs) were dispersed in 10 mL of PBS. This step was repeated at least five times. The 
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purified RBCs were diluted in 10 mL of PBS and kept on ice during the sample preparation. 0.1 
mL of RBC solution was added to 0.4 mL of nanoparticle (NP) solution in PBS in 1.5 mL 
centrifuge tube (Fisher) and mixed gently by pipetting. RBCs incubated with PBS and water were 
used as negative and positive control, respectively. All NP samples as well as controls were 
prepared in triplicate. The mixture was incubated at 37 ˚C for 30 minutes while shaking at 150 
r.p.m. After incubation period, the solution was centrifuged at 4000 r.p.m. for 5 minutes and 100 
μL of supernatant was transferred to a 96-well plate. The absorbance value of the supernatant was 
measured at 570 nm using a microplate reader (SpectraMax M2, Molecular devices) with 
absorbance at 655 nm as a reference. The percent hemolysis was calculated using the following 
formula: 
 
% Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 
absorbance-negative control absorbance)) × 100. 
 
Hemolysis assay in the presence of plasma proteins: Human plasma (pooled, mixed 
gender) were purchased from Biochemed Pharmaceuticals, VA and kept at -20 ˚C for further use. 
NPs were pre-incubated in 55% of plasma solution in PBS (v/v) for 30 minutes at 37 ˚C. After the 
pre-incubation period, 0.1 mL of washed RBCs were added to the solution and further incubated 
for 30 minutes or 24 hours. The same procedure was followed to determine the hemolysis in the 
presence of plasma (vide supra). 
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CHAPTER 5 
NANOPARTICLE SURFACE FUNCTIONALITY DICTATES PROTEIN 
CORONA FORMATION AND MACROPHAGE RECOGNITION 
5.1. Introduction 
When NPs (NPs) are exposed to complex biofluids (e.g. blood, plasma), it immediately 
adsorbs proteins on its surface, forming a layer of proteins, namely “protein corona" that 
effectively mask the original chemical nature.1 This non-specific adsorption of proteins on NP 
surfaces is highly critical for delivery applications because the adsorption of opsonin proteins 
from blood (e.g. immunoglobulins) increase the clearance rate of NPs via the reticulo-endothelial 
system and decrease the pharmacokinetic half-life of NPs in vivo.2 Blood plasma contains 
thousands of proteins that can bind to NPs with the interaction profile strongly depending on the 
NP surface chemistry.3 For example, positively charged polystyrene particles were shown to 
interact with proteins with isoelectric points less than 5.5 (e.g. serum albumin) while negatively 
charged particles preferentially bind to proteins with isoelectric points higher than 5.5 (e.g. IgG).4 
This demonstrates the binding of NPs to proteins can be electrostatic in nature. Moreover, 
negatively charged polymeric NPs of similar size and hydrophobicity adsorb higher amount of 
proteins on their surfaces with increasing surface charge density; however, the identity of the 
adsorbed proteins were very similar.5  
The hydrophobicity of the NP surface is also a key parameter in NP-protein interactions.6 
For example, hydrophobic N-isopropylacrylamide-co-N-tert-butylacrylamide (NIPAM/BAM) 
copolymer NPs were shown to adsorb a higher amount of protein on their surfaces than their 
hydrophilic counterparts,7 presumably due to greater affinity and/or increased number of binding 
sites on hydrophobic NP surfaces.8 The identity of the protein corona formed on the surface is 
also dependent on the NP surface hydrophobicity. For example, hydrophobic NPs adsorb 
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apolipoproteins on their surface while adsorption of more abundant hydrophilic proteins 
including albumin and IgG were observed in the corona of hydrophilic NPs.9 
In addition to charge and hydrophobicity, the presence of specific functional groups on 
NP surface also dictates the interaction of proteins with NPs. For example, Shea et al. have 
synthesized three different cationic NIPAM polymeric NPs featuring guanidinium, primary 
amino, and quaternary ammonium functional groups. A significant higher binding was observed 
for the guanidinium functionalized polymer NPs towards fibrinogen. This specific chemical 
structure-dependent interaction was due to the strong interactions of guanidinium groups with 
surface carboxylate groups on fibrinogen. 10 Likewise, methylstyrene-featuring NPs (~90 nm) 
showed significantly higher binding of plasma proteins compared to tert-butylstyrene 
functionalized NPs of similar charge.6 
Even though numerous studies have documented the effect of surface chemistry on the 
formation of plasma protein coronas, a clear structure-function relationship still remains elusive. 
The use of disorganized array of particle sizes, shapes, and coverages with little to no therapeutic 
values also makes it challenging to deduce general conclusion that can be applied to ‘real’ drug 
delivery systems. In prior studies, we have shown that blood half life of surface engineered 
cationic gold NPs is lower than NPs featuring other charges (Neutral, anionic, and negative).11  
Moreover, the biodistribution of the surface engineered cationic NPs were strictly dependent on 
their surface hydrophobicity;  gold NPs featuring the most hydrophobic headgroup had significant 
accumulation in liver while AuNPs with moderate hydrophobicity showed higher accumulation in 
spleen.12 The significant accumulation of these NPs in liver and spleen also suggests their rapid 
uptake by liver and splenic macrophages and subsequent phagocytic clearance. Therefore, 
understanding the effect of engineered surface functionality on macrophage recognition can aid in 
design delivery vehicles with improved selectivity and longer pharmacokinetic profile. 
Herein, we have studied a systematic understanding of the role of NP surface 
functionality on the formation of protein corona and investigated the uptake of NPs in 
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macrophage cells. Using a semi-quantitative proteomics approach we have shown that the 
specific chemical moieties on the NP surface adsorb a variety of proteins of different amount and 
identity. In particular, NPs with similar hydrophobicity but constitutional isomers also showed 
different corona type and uptake pattern, arising due to the recognition of specific functional 
group on NP surface. 
5.2. Results and Discussion 
All NPs were synthesized from a 2 nm core pentanethiol capped gold NPs13 via place 
exchange reaction14 and have similar hydrodynamic diameter and zeta potential value, making 
them an ideal platform to study the sole effect of NP surface functionality. A critical point in the 
design of these NPs is the inclusion of a non-interacting biocompatible spacer tetra(ethylene 
glycol) that prevents aggregation, and more importantly, allows specific chemical groups to be 
exposed to the NP surface (the interacting zone). Hydrophobicity was chosen as the chemical 
variable due to the significant role played by this parameter at the nano-bio interface, including 
protein-NP interaction,15,16 cellular uptake,17 toxicity,18,19 and immune system recognition.20,21 
(Figure 5.1). Most importantly, the atomic level control of the design allowed us to fabricate NP 
bearing constitutional isomeric headgroups (e.g. NP5 and NP6) to probe their effect on the 
protein binding and macrophage uptake. 
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Figure 5.1. Gold NPs used in this study to investigate the identity of protein corona formation 
and macrophage uptake. LogP denotes the relative hydrophobic index of the functional 
headgroups. 
Previously we have demonstrated that cationic NPs can effectively bind to the anionic 
proteins at physiological pH.22 However, this one model protein can not address the complex 
nature of NP-protein interaction in serum which contains thousands of proteins. To this end, we 
have studied the protein interaction in 10% and 50% serum, mimicking in vitro and in vivo 
conditions. Previous literature have demonstrated that NP-bound serum proteins have two 
different layer, ‘soft’ corona (reversibly bound proteins) and ‘hard’ corona (irreversibly bound 
proteins).23 Hard corona proteins tend to stick with NPs for longer time and dictate the NP 
biodistribution and macrophage uptake. We have studied the identity of hard corona proteins 
using liquid chromatography tandem mass spectrometry (LC-MS/MS).24 The NPs were incubated 
with different concentrations of serum proteins followed by centrifugation, and then washed 
multiple times to remove soft corona proteins and were subjected to LC-MS/MS analysis.       
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Table 5.1. Abundant proteins observed in the hard corona of NP1 to NP6 
 Mw Proteins Gene pI Function 
30778 Apolipoprotein A-I  APOA1 5.72 Lipid transport 
10852 Apolipoprotein C-III  APOC3 5.23 Lipid transport 
11609 Ig kappa chain C region  IGKC 9.01 Immune response 
51790 Ig mu chain C region IGHM 6.56 Immune response 
8168 Immunoglobulin J chain IGJ 5.09 Immune response 
187147 Complement C3  C3 6.02 Complement activation  
26459 Complement C1q 
subcomponent subunit B  
C1QB 8.83 Complement activation 
 
Although other studies identified numerous proteins in the hard corona composition,25 we 
have successfully identified nearly 100 different types of proteins in our NP samples. Table 5.1 
demonstrates the highly abundant proteins bound to all of the NPs irrespective of their surface 
functionality. First, the analysis showed that the hard corona protein found on the NP surface 
does not correspond to their abundance in serum. For example, albumin is the most abundant 
protein in serum (comprises ~60-70% of serum proteins) but it was not the highest abundant 
protein in the corona. Instead, corona was enriched with mostly lipoproteins (~25% of total 
corona proteins) that have low abundance in serum (~5%). Second, the most abundant proteins 
adsorbed on NP surface have pI<7, demonstrating the binding is mostly due to the electrostatic 
association. 
Figure 5.2 depicts a concise picture of the corona proteins identified when NPs were 
incubated in 10% serum sample. Clearly, the majority of the proteins observed in the corona are 
the proteins from extracellular region or space, attesting the reliability of the method of detection. 
The analysis also revealed that the majority of the proteins bound to all of the NPs irrespective of 
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their functionality are lipoproteins, immunoglobulins, and complement system proteins (70-80% 
of total proteins). Previous studies have demonstrated that NPs with higher hydrophobicity tend 
to bind more lipoproteins,9 however, we observed a decreasing amount of bound lipoproteins on 
NPs with higher hydrophobicity, a strikingly opposite observation in case of surface engineered 
NPs. This provides direct evidence that the binding of functionalized NPs with serum proteins 
can be significantly altered compared to bare NPs. However, no direct trend was observed for 
NPs bound to other type of protein classes, demonstrating major influence of lipoproteins over 
other classes in the binding process towards hydrophobic NPs. Significantly NP5 and NP6 have 
distinctly different immunoglobulin binding profile despite being constitutional isomers, 
signifying that functionality of headgroup (branched vs linear) plays a critical role on protein 
corona formation. Likewise, NP3 and NP4 (cyclic vs. linear chain) also demonstrated different 
binding of coagulation and complement, attesting to the importance of monolayer functionality 
on the proteomic profile. In general, linear structured NPs adsorbed fewer proteins of different 
classes (acute phase, complement, coagulation, immunoglobulins) in 10% serum compared to 
their cyclic and branched counterpart (Figure 5.2), an important criterion that can be crucial for 
nanomaterial design for in vivo applications. 
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Figure 5.2. Classification of identified corona proteins for NP1-NP6 in 10% human serum. The 
proteins were classified in five major classes according to their biological function in blood. 
The concentration of serum, however, is close to 50% in blood. We, therefore, further 
investigated the protein binding profile of our NPs in 50% human serum solution (Figure 5.3). 
Few important observations were noted in the data obtained in higher serum concentrations. First, 
the major difference between 10% and 50% data was the number of proteins identified on NPs in 
50% serum is lower (50-60) than the 10% serum samples (70-100). This might be due to the fact 
that in diluted serum samples (10%) NPs have higher chances to interact with non-abundant 
proteins (interaction is more reversible) while at high serum concentrations the abundant proteins 
mask NP surfaces more efficiently (not fully reversible), thereby hindering access to other type of 
proteins in the serum. Second, the amount and the identity of the corona profile were significantly 
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varied in the presence of higher serum amount. For example, in 10% serum sample, hydrophobic 
NPs bound less lipoproteins but in 50% serum NP4 has the highest lipoproteins binding 
compared to other NPs. However, the common trend of lower binding of immunoglobulins and 
complement proteins can still be observed in case of linear structured NPs (NP4 and NP6) 
compared to the either branched (NP5) or cyclic (NP3) counterparts. Since immunoglobulins and 
complement factors are important classes of proteins known for facilitating opsonization process, 
this atomic level control of design can evade immune system recognition and improve 
pharmacokinetic profile of NPs in blood. Taken together, NP surface functionality dictates the 
binding of serum proteins on its surface. Importantly, NPs featuring constitutional isomeric 
headgroups showed different binding profile of serum proteins, indicating the significance of 
chemical design in developing therapeutic NPs. Linear structured hydrophobic NPs bound less 
immunoglobulins and complement proteins in both 10% and 50% serum samples, providing an 
important design parameter for in vivo applications.  
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Figure 5.3. Classification of identified corona proteins for NP1-NP6 in 50% serum. The proteins 
were classified in five major classes according to their biological function in blood. 
Opsonization of the foreign substances via immunoglobulins and complement proteins is 
the key step through which tissue resident macrophages can remove the foreign 
pathogens/substances from the blood.26 Since all of the NPs tested in this study showed binding 
to immunoglobulins and complement factors, we hypothesized that the differential amount and 
identity of bound proteins can regulate the uptake of these NPs in macrophages. We have chosen 
a murine macrophage cell line RAW 264.7 to study the uptake both in the presence and absence 
of 10% serum. As depicted in figure 5.4a, NP uptake was strongly dependent on the surface 
functionality. Clearly, without serum the uptake of NP4 and NP6 was lower compared to their 
cyclic (NP3) and branched (NP5) counterpart, demonstrating the lack of recognition process of 
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linear surface functionality towards both proteins and cells. Interestingly, in the presence of 
serum, a nearly 20 fold decrease in uptake was observed (Figure 5.4b), indicating the effective 
masking of NP surface functionality by serum proteins and subsequent low uptake in macrophage 
cells. However, the hydrophobic NPs showed lower uptake compared to hydrophilic ones (NP1 
and NP2) in the presence of serum proteins. This result mirrors our previous finding where a 
linear trend in NP surface hydrophobicity and cellular uptake was observed in HeLa cells.17 Most 
importantly, although NP5 and NP6 showed similar uptake behavior in the absence of serum, a 
significant difference in uptake was observed in presence of serum, signifying the role of specific 
chemical group on NP surface on macrophage recognition. 
 
Figure 5.4. Uptake of NP1-NP6 (50 nM each) in murine macrophage cells RAW 264.7 after 3 h 
(a) without and (b) with 10% serum. 
Recognition of specific chemical moieties by antigen presenting cells (e.g. macrophages) 
is central to the innate immune response.27 To understand the effect of surface functional group 
towards macrophage recognition, we have studied the pro-inflammatory cytokine TNFα 
generation upon interaction with NP1-NP6 in RAW cells both in the presence and absence of 
serum proteins (Figure 5.5). Although we did not observe a strong immune response for most of 
the NPs at the concentration tested compared to the positive control lipopolysaccharide (LPS, 
1μg/mL), NP4 produced a strikingly high amount of TNFα (~70% compared to LPS) in RAW 
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cells. This is presumably due to the direct recognition of cyclic headgroup on NP surface to the 
macrophage surface receptor Toll-like receptor 4. However, as expected, in the presence of serum 
the NP surface was masked and all NPs showed no TNFα production compared to the negative 
control (cell only). Taken together, the interplay of NP surface functionality and protein corona 
formation dictates the macrophage uptake and rescue cells from pro-inflammation. 
 
Figure 5.5. % Production of tumor necrosis factor alpha in RAW 264.7 cells after 6 h of 
incubation with NP1-NP6 (50 nM each) (a) without and (b) with 10% serum. 
5.3. Conclusions  
The surface functionality of NPs creates an effective interface between nanomaterials and 
biosystems. Using a semi-quantitative proteomics approach, we have demonstrated that the 
specific chemical moieties on the NP surface adsorb a variety of proteins of different amount and 
identity. Importantly, the linear functional group binds to fewer amounts of immunoglobulins and 
complement proteins compared to cyclic and branched counterpart in both low and high serum 
conditions, providing a design parameter for future delivery vehicles. Uptake in macrophage 
revealed a linear dependency of surface hydrophobicity; lower uptake was observed for NPs with 
higher hydrophobicity. Cyclic chemical group produced a strong pro-inflammatory response in 
the absence of serum, however, the presence of serum completely nullify the pro-inflammation. 
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Understanding the effect of surface functionality on NP interaction with serum proteins can 
predict the key pharmacokinetic parameters including biodistribution, recognition by 
mononuclear phagocytic system and subsequent clearance. 
5.4. Experimental Section 
NP synthesis: All NPs were synthesized according to previously published procedure. 28 
Protein isolation and mass spectrometric detection: 100 μL of AuNPs (1μM) were 
mixed with 900 μL of human serum (with various concentrations) and incubated for 1h at 37 ˚C. 
The mixture were then centrifuged at 13 000g at 15 ˚C for 30 min. The supernatant was removed 
and the collected corona coated AuNPs was redispersed in 500 μL of cold (15 ˚C) phosphate 
buffered saline (PBS). The solution was centrifuged again (at the same condition) and the 
collected particles was redispersed in 500 μL of cold (15 ˚C) PBS. After another centrifugation 
process, the hard corona coated particles were introduced to LC MS/MS procedure. 
Mass spectrometric detection of NP-bound proteins: The liquid chromatography 
tandem mass sprectrometric characterization of NP bound proteins was performed according to 
the previously published procedure.29 In order to obtain the total number of the LC MS/MS 
spectra for all of the peptides that are attributed to a matched protein, a semi-quantitative 
assessment of the protein amounts was conducted through application of spectral counting 
method. The normalized SpC amounts of each protein, identified in the MS study of smooth and 
jagged surfaces, were calculated by applying the following equation  
                                        
Where NpSpCk is the normalized percentage of spectral count (i.e., raw counts of ions) 
for protein k, SpC is the spectral count identified, and Mw is the molecular weight (in kDa) of the 
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protein k. Using this equation, one can expect to obtain the protein size and to evaluate the real 
contribution of each protein to the hard corona composition. 
Cellular uptake: RAW 264.7 cells (murine macrophage) were cultured at 37 °C under a 
humidified atmosphere of 5 % CO2. The cells were grown in RPMI media containing 10 % fetal 
bovine serum (FBS) and 1% antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). For 
the uptake experiment, 250,000 cells/well were plated in a 48-well plate prior to the experiment. 
On the following day, cells were washed one time with PBS followed by NP treatment (50 
nM/well) and further incubated with or without 10% serum for 3 h. Following incubation, cells 
were washed three times with PBS, lysed and the intracellular gold amount was measured using 
inductively coupled plasma mass spectrometry (Elan 6100, Perkin-Elmer, Shelton, CT, USA). 
Each cell uptake experiment was done in triplicate, and each replicate was measured 5 times by 
ICP-MS. ICP-MS operating conditions are as below: rf power 1600 W; plasma Ar Flow rate, 15 
ml/min, nebulizer Ar flow rate, 0.98 ml/min and dwell time, 45 ms. 
Cytokine measurement: RAW 264.7 cells were seeded at a density of 500000 cells/well 
prior to the experiment. On the following day, cells were washed one time with PBS followed by 
NP treatment (50 nM/well) and further incubated with or without 10% serum for 6 h. After 
incubation, the supernatant were collected from each well. TNFα expression was evaluated using 
ELISA. Briefly, 100uL of a solution of anti-mouse/rat TNF antibody (1:1000 from 0.5mg/mL 
stock) were poured into the wells of a 96 well plate and incubated at 4°C overnight. The plate was 
then washed 3 times using a solution of tween 20 (0.05% v/v), and 200uL of blocking solution 
(1% BSA in PBS) were added to the plate with incubation for 3 hours at room temperature. The 
plate was then washed again, and 100uL of the samples (undiluted media from the cell culture) 
were added to the wells along with TNFα standards. The plate was incubated overnight at 4°C 
and after that it was washed again. A solution of Biotin Human anti-mouse/rat antibody (1:1000 
from 0.5mg/mL stock) was added to the plate and incubated at room temperature for 1 h. A new 
washing was performed and a solution of Avidin-HRP (100 uL of 1:500 from stock) was added to 
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the wells. After incubation for 1 h, a final washing step was performed and 100uL TMB substrate 
reagent set were added to the wells. When blue coloration started to appear 50uL of stop solution 
(2N H2SO4) were added. The absorbance of the samples was the recorded at 450nm on a Biotek 
synergy 2 plate reader. 
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CHAPTER 6 
FABRICATION OF ZWITTERIONIC NANOPARTICLES WITH TUNABLE 
HYDROPHOBICITY 
6.1. Introduction 
Surface functionalization of nanoparticles (NPs) is an essential tool to modulate the 
behavior of these materials both in vitro and in vivo.1, 2 The biodistribution,3 toxicity4 and 
clearance5,6 of nanomaterials can be regulated through controlled chemical modifications. 
However, when NPs are exposed to biofluids, such as plasma or serum, proteins and other 
biomolecules adsorb on the surface of these materials (Figure 6.1a).7-9 This in situ formation of a 
“protein corona” 10,11 masks the engineered functionalities on the nanoparticle surfaces, 
dramatically changing the nature of their interaction with biosystems.12- 14 For example, the 
targeting efficacy of antibody-functionalized NPs are compromised due to the high levels of 
opsonization.15,16 Likewise, the study of correlations between surface functionality and biological 
activity is challenging, as the results are subject to the interplay between the chemical moieties 
and the corona, rather than depending on the functionalities themselves.17,18 
Many approaches have been investigated to prevent the formation of the protein corona 
to provide NPs with non-fouling properties. One classical approach is the use of a non-charged 
poly(ethylene glycol) (PEG) polymer that prevents the NP from adsorbing proteins.19,20 However, 
it has been observed that PEG-functionalized NPs do indeed interact with certain plasma proteins, 
inducing the activation of different immune responses.21 Moreover, systematic changes in the 
surface properties of PEG functionalized NPs are difficult to achieve as the absence of charge 
allows the internalization of pendant hydrophobic functionalities, reducing exposure.22 An 
alternative to the use of PEG is the incorporation of zwitterion functionalities onto the NP 
surface, including amino acids23 and polybetaines.24The strong electrostatic binding of water with 
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zwitterions (as opposed to water hydrogen bonding with PEG) has been postulated as the 
rationale behind the high degree of stability and non-fouling properties observed with zwitterionic 
systems.25 However, pH dependence of carboxy-based systems26 and the difficulty of systematic 
functionalization27,28 limit the ability to control surface properties while maintaining 
biocompatibility and corona-free character. 
Herein, we report the synthesis and use of a new family of NP surface coverages that 
exhibit tunable hydrophobicity while preventing the formation of a protein corona. This 
nanoparticle ligand design maintains corona-free behavior at moderate protein levels and prevents 
the irreversible formation of “hard” corona at physiological serum concentrations, while allowing 
properties such as hydrophobicity to be varied. These “naked” particles allow a systematic 
molecular structure-based assessment of the effects caused directly by the NP surface, including 
cellular uptake and hemolytic activity. 
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Figure 6.1. (a) Reversible adsorption of proteins and formation of irreversible hard corona over 
the NP surface. (b) Structures of the non-fouling NPs, along with TEG, NP+ and NP- controls. 
The ligand structure consists of a hydrophobic interior that confers stability to the NP core, an 
oligo(ethylene glycol) chain used as a first layer for biocompatibility, and the zwitterionic 
headgroups to confer ultra-fouling properties. The zwitterionic headgroups (the NP surface) differ 
only in their hydrophobicity, whose relative values can be estimated by the calculated Log P of 
the terminal functionality. (c) Correlation of the calculated Log P with toluene/water interfacial 
tension. 
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6.2. Results and Discussion 
The chemical design of the NP ligand is based on a combination of a short oligo(ethylene 
glycol) spacer with sulfobetaine termini (Figure 6.1b). This combination has shown to provide 
better stealth properties to NPs compared to the ethylene glycol chains alone.29 Hydrophobicity 
was chosen as the chemical variable due to the significant role played by this parameter at the 
nano-bio interface, including protein-NP interaction,30,31 cellular uptake,18 toxicity,32,33 and 
immune system recognition.34,35 The degree of surface hydrophobicity was controlled with these 
ligands by systematically engineering the quaternary ammonium nitrogen (Figure 6.1b). All 
particles were fabricated from a 2 nm gold core, a factor that contributes to the observed corona-
free character, given the reduced protein adsorption7 and the increased plasma stability of small 
nanoparticles.36  
A numerical descriptor is commonly employed in SAR studies to represent the property 
that is being tested. Computational calculation of the n-octanol/water partition coefficient of the 
NP headgroups (Log P of R groups, Figure 6.1b) provides a readily accessible means to describe 
the relative hydrophobicity of NPs.37 These calculated values were correlated with water/toluene 
interfacial tension (IFT) measurements, a technique that has been used to describe the effective 
surface hydrophobicity of NPs independent of the material of origin.38 As can be observed in 
Figure 6.1c, the calculated Log P values and the experimental IFT results are essentially linearly 
correlated, indicating that the hydrophobicity of the NPs is predicted by the Log P descriptor. The 
very low threshold of values of the IFT of these NPs evidenced their high degree of 
amphiphilicity, a characteristic that is on favor of their colloidal stability despite the overall 
neutral zeta potential. ZDiPen represents the limit in terms of hydrophobicity: if the Log P of the 
headgroup is above 4.5 (IFT<0), or if the length of the straight-chain substituents is larger than 
six carbons, the NPs were insoluble in water. 
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To determine the preliminary interactions of the synthesized NPs with proteins,26, 39 
dynamic light scattering (DLS) measurements were recorded in the presence of 1% serum, the 
highest concentration that did not overwhelm the NP signal. The principal change in the DLS 
profile of serum after the addition of NP+ (cationic), NP- (anionic) and TEG (neutral oligo 
(ethylene glycol) capped particles) was the shift of the ~9 nm hydrodynamic diameter (dh) peak to 
~20 nm, evidencing the formation of discrete protein-NP complexes, namely the protein corona 
(Figure 6.2a and 6.2b). For NP+, the formation of a peak above 1000 nm was also observed 
indicating the presence of extended protein-NP aggregates. In contrast, only the peak at ~9 nm 
was observed with the zwitterionic NPs ZMe to ZDiPen (Figures 6.2a and 6.2b). These results 
can easily be contrasted by comparing the predicted histogram in the case where no corona is 
formed (the addition of the individual serum and NP histograms) with the experimental DLS 
distribution after mixing the NPs with serum (Figure 6.2c). As observed in Figure 6.2d, the 
subtraction of the experimental histograms from the predicted additive histograms shows that 
while NP+ presents residuals at the ~20 nm and ~1000 nm zones indicative of both aggregation 
and corona formation, ZMe has minimal residual, indicating the absence of corona at these 
protein levels. 
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Figure 6.2. (a) Particle size distribution for cationic NP+ and zwitterionic particle ZMe in the 
presence and absence of serum proteins (1% serum, background) evidencing the formation of 
NP/protein complexes (~20 nm) with NP+ but not with ZMe (b) Lack of corona formation for 
zwitterionic particles in serum, and corona formation for TEG (lacking zwitterionic headgroup) 
and anionic NP-. (c) Comparison between the experimental DLS profiles of each NP in serum 
with the additive histogram of the combination of the individual serum and NP. (d) Residuals of 
the spectrums in serum after removing the individual NP and serum histograms, evidencing 
corona and aggregate formation for NP+ with minimal residual observed for ZMe (e) Dilution 
studies showing lack of hard corona formation for ZMe after incubation in 55% human serum, 
with contrasting behavior by the cationic NP+ particle. (f) Sedimentation experiments for the 
series of NPs in 55% plasma showing that zwitterionic NPs ZMe to ZDiPen did not aggregate, in 
contrast to NP+, NP-, and TEG that formed pellets. 
Corona formation involves both reversible and irreversible (hard corona) adsorption of 
proteins on the NP surface (Figure 6.1a).40, 41, 42 While we were unable to verify the lack of 
reversible protein adsorption at physiological serum concentrations, we were able to verify the 
absence of hard corona formation on zwitterionic NPs through incubation and dilution. For this 
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purpose, we incubated the set of NPs with 55% human serum at 37°C for 30 min, diluted the 
solutions and recorded DLS measurements to observe if irreversible protein-NP interactions had 
occurred for the controls and if crowding effects may alter the absence of corona for the 
zwitterionic NPs. As observed in Figure 6.2e, although the peak of the NP-protein conjugates 
(>1000 nm) for NP+ decreased when the sample was diluted, the peak at ~20 nm that describes 
discrete NP-protein complexes remained present after dilution, indicating a strong irreversible 
protein binding (hard corona). Similar results were obtained for NP- and TEG, suggesting that the 
larger protein-NP conjugates dissociated and only the discrete ones remained after dilution 
(Figure 6.4). In contrast, for NPs ZMe-ZDiPen (Figure 6.2e and 6.4), the ~9 nm peak was the 
only one observed, indicating the absence of an irreversible protein layer (hard corona). 
Further studies using electrophoresis established that zwitterionic particles ZMe-ZDiPen 
are non-interacting in plasma (55% in PBS, v/v), a more complex matrix. As expected, the 
mobilities of cationic NP+ and anionic NP- were affected by the presence of proteins due to the 
corona formation. In contrast, similar mobilities were observed for the zwitterionic NPs in the 
presence and absence of plasma proteins (Figure 6.5). Likewise, TEG presented a minimal 
difference between the two conditions, and the subtle band movement in presence of protein 
presumably occurs due to NP aggregation. Despite these results, gel electrophoresis does not 
provide a definitive result on the absence of corona formation due to the poor mobility of all of 
the NPs in the agarose matrix. To further corroborate our hypothesis, sedimentation experiments 
were performed in the presence of 10%, 55% and undiluted plasma, mimicking in vitro and in 
vivo conditions.42 As expected, while NP+ formed a pellet, NPs ZMe to ZDiPen presented 
minimal or no aggregates even at physiological plasma levels (Figure 6.2f and Figure 6.6a). 
These qualitative observations were validated by UV measurements of the supernatants before 
and after the sedimentation process (Figure 6.6b). NP- presented a pellet of smaller size than 
NP+, result that correlates with the observations by DLS and gel electrophoresis. Significantly, 
TEG NP presented sedimentation similar to the one observed for NP+. This outcome mirrors the 
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results from DLS experiments and is consistent with previous findings that postulate the 
recognition of PEG functionalities by proteins of the bloodstream.21  
We wanted to observe if we were able to obtain pellets for the zwitterionic NPs using 
other variants of the sedimentation experiments, and also confirm that the sedimentation of NP+ 
was due to the formation of corona and no simple NP precipitation. To this end we repeated the 
sedimentation experiments using different sucrose gradients, a technique that has been used to 
separate NP/protein complexes from NPs alone.14 Under these conditions we obtained similar 
results as with the direct sedimentation experiments, with a thick pellet only observed for NP+. 
We further ran a SDS-PAGE gel treating all the samples as if precipitation was observed, and 
from the results it can be observed that NP+ did adsorb proteins over the surface while ZMe-
ZDiPen behave as the negative control (serum only, no NPs added, Figure 6.7). This further 
confirms the absence of irreversible protein adsorption over the surface of zwitterionic NPs at 
physiological protein levels. It is important to note that we did observe a very faint precipitation 
for the more hydrophobic NPs, however this precipitate was redissolved in the washing steps with 
PBS (intended to remove loosely bound proteins). This result indicates that even if NP/protein 
interactions are observed at large values of hydrophobicity, these interactions are reversible and 
no hard corona is formed.  
Once the absence of corona was established, we investigated the effects of NP 
hydrophobicity on cellular uptake,43 a phenomenon critically affected by the NP surface and the 
protein corona.44, 45, 46 For this purpose, uptake studies were performed in serum-containing and 
serum-free media, conditions that critically affect the trend of uptake of NPs of varying 
hydrophobicity.18 As seen in Figure 6.3a, there was an increase in cellular uptake with increasing 
surface hydrophobicity for both cases. In previous studies, when NPs were exposed to the cells in 
serum-free conditions, increasing hydrophobicity increased cell uptake, similar to the results that 
we obtained.18 However when the studies were performed in media with serum, increasing the 
hydrophobicity of NPs lead to greater protein adsorption over the NP surface,47 which in turn 
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reduced the cellular uptake.48,49 In contrast to these prior systems, we obtained similar cellular 
uptake trends for NPs ZMe-ZDiPen both in the presence and absence of serum. This result 
indicates that direct correlations between the NP surface chemistry and biological responses can 
be assessed using these NPs, providing further proof of the absence of proteins on the NP 
surfaces and the direct presentation of the chemical motifs to the cell surface. As expected, 
overall uptake was low50 and there was a marked difference in the absolute amount of NP uptake 
in the presence and absence of serum (~2 fold higher uptake without serum). This latter 
phenomenon has been observed previously for other particles independent of their charge,51,52 
possibly due to non-specific binding of proteins and NPs to the cell membrane, a competitive 
process that slows the uptake of NPs when proteins are present.52, 17 Finally, it is important to note 
that at the condition of the study the nanoparticles were non-cytotoxic (Figure 6.8). 
 
Figure 6.3. (a) Cellular uptake (MCF-7 cells, 3h) of zwitterionic NPs ZMe to ZDiPen and NP+ in 
presence and absence (inset) of serum, showing similar uptake trends for both experimental 
conditions. (b) Hemolytic activity of the NPs at different time points and in the presence and 
absence of plasma (NPs at a concentration of 500nM unless otherwise stated). 
 
Due to the corona-free character, these NPs have the potential for long circulation times53 
increasing the possibility of hemolytic activity. As such, hemolytic assays were performed as a 
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means to probe the compatibility of the NPs with red blood cells (RBCs).54, 55 NPs ZMe to 
ZDiPen were incubated with RBCs isolated from commercially purchased human whole blood. 
The experiments were performed both in the presence and in the absence of blood plasma. 56 The 
results (Figure 6.3b) provide evidence that no significant cell lysis was elicited by the zwitterionic 
NPs either in the presence or in the absence of plasma. Hemolytic activity was only observed for 
the more hydrophobic NP (ZDiPen) at 24h without plasma proteins, consistent with a critical 
change in the behavior of NPs at extreme values of hydrophobicity. However, it is important to 
note that during the half-life that is expected for these particles (~6h),37 no significant hemolytic 
response was observed in the presence of plasma proteins for the zwitterionic NPs. 
6.3. Conclusions 
In summary, we have demonstrated that sulfobetaine headgroups can be engineered to 
provide particles with controlled hydrophobicity. These particles do not adsorb proteins at 
moderate serum protein concentrations nor do they form a hard corona at physiological serum 
conditions. The ligand design provides the potential to directly control the interaction of the 
nanomaterials with biosystems without interference from protein binding. As such, these 
coverages provide promising scaffolds for delivery vehicles and self-therapeutic systems. They 
also open new avenues for probing the fundamental nature of the nano-bio interface through 
direct interfacing of synthetic and biological components without intermediary complications 
arising from the protein corona. 
6.4. Experimental Section 
Nanoparticle synthesis and characterization: To a solution of gold nanoparticle (NP) 
cores coated with a monolayer of 1-pentanethiol (~2nm core diameter, synthesized by the Brust-
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Schiffrin methodology57 and purified to remove the phase transfer catalyst58) in dry 
dichloromethane (DCM) and methanol (MeOH) (9.5:0.5), a solution of the respective ligands in 
the same solvent was added, maintaining an inert atmosphere and constantly stirring for 3 days 
(5:1 w/w ratio of ligand/gold cores).59 The solvent was evaporated and the remaining dark 
residue was washed several times with DCM or ethyl acetate until no smell was detected 
(removal of 1-pentanethiol). The nanoparticles were dispersed in distilled water, and dispensed 
into a membrane bag (~10,000 pore size) for dialysis purification for 5 days. Water was removed 
by lyophilization and the final product was redispersed in MQ deionized water (or D2O), and the 
concentration of the final solution was determined using UV absorption according to the reported 
procedure.60 The functionalized gold nanoparticles were characterized by 1HNMR (Bruker 
Avance 400 MHz, 600 scans, [NP]=20μM), MALDI-MS (Bruker Autoflex III MALDI-TOF MS, 
200 shots-20 off-laser 55%, suppress up to 400Da), DLS and ZP (Malvern NanoZeta Sizer, 
[NP]=1 μM) to observe the chemical composition of the monolayer, the hydrodynamic size, and 
the surface zeta potential. The LogP values of the ligand headgroups (R groups of Figure 6.1) 
were estimated using ChemDraw Ultra 12.0. 
Interfacial Tension. The dynamic interfacial tension of the NPs at the toluene−water 
interface was measured by the pendant drop method using an OCA20 measuring instrument 
(Dataphysics, Stuttgart). A syringe filled with an aqueous solution of NPs (1µM) connected to a 
blunt needle was fixed vertically with the needle immersed in the toluene phase. A small amount 
of solution was injected from the syringe to form a drop. The variation of drop shape with time 
until equilibrium (interfacial tension) and drop fall was captured by automated camera. The 
measurements were performed in triplicate. 
Dynamic Light Scattering. DLS profiles were recorded in 1% human serum (~16 µM 
protein concentration) diluted in phosphate buffered saline (PBS, pH 7.4) at 37 °C with NPs at a 
concentration of 1µM using a Malvern Zetasizer Nano ZS. For the dilution profiles, NPs at a 
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concentration of 50 µM were incubated for 30 min at 37 °C in 55% human serum, then diluted 
accordingly. The subtraction of the individual NP and serum spectrums from the ‘NP in serum’ 
results, was done point by point using normalized data to take into account the concentration of 
each species (spectra of individual NPs and serum reported as normalized). The results are 
reported as %Number when individual NPs are analyzed (characterization) and as %Volume for 
the NP/Protein mixtures due to the dependence on the different refractive index of each entity. 
Sedimentation. To a solution of 10%, 55% plasma (in PBS) and undiluted plasma, NPs 
were added to achieve a final concentration of 500nM (500µL total volume). The solutions were 
incubated for 5 minutes, and the tubes were subjected to centrifugation for 30 min at 14,000 
r.p.m. After centrifugation, 200 µL of the supernatant was transferred to a 96-well plate alongside 
200 µL of the same mixture before the centrifugation. The absorbance values were measured at 
506 nm, which is the wavelength at which NP concentration is determined. The absorbance 
generated by the proteins was subtracted using a blank protein sample with no particles. UV 
differences were significant only at 10% plasma, as the proteins have much more interference at 
55% plasma. All NPs and blank samples were prepared in triplicate. For the sucrose gradients, 
NP samples in undiluted serum/plasma were centrifuged at 14,000 rpm during 30 min using a 
sequential gradient of 24%, 12% and 6% sucrose, and a sharp gradient of 24% for the gel. 
Ultracentrifugation experiments were run at 60,000 rpm for 1h. 
Agarose gel electrophoresis. Agarose gels were prepared in PBS at a 0.5% final agarose 
concentration. NPs at a concentration of 1 µM were incubated with or without 55% plasma in 
PBS for 15 min, and 2 uL of 50% glycerol were added to the solution to ensure proper gel 
loading. The mixture was loaded in each well and the gels were run at a constant voltage of 100V 
for 30 min.  
Protein isolation from NPs and SDS-polyacrylamide gel electrophoresis. NP+ and 
NPs ZMe-ZDiPen (0.5µM) were incubated in undiluted human serum for 24h at 37°C. After 
incubation, serum-NP mixtures were loaded onto a sucrose cushion (24%) to rapidly separate NP-
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protein complexes from serum by centrifugation at 14,000rpm for 30min.14 The supernatant was 
carefully removed and the residues were washed with 1mL PBS three times. Proteins were eluted 
from the nanoparticles by adding 4x Laemmli sample buffer (Biorad 161-0747) with 2-
mercaptoethanol to the pellet and subsequent incubation at 95°C for 5min. For 1D gel 
electrophoresis, 20µL of recovered proteins in sample buffer were separated on a 12% SDS-
PAGE gel. Gels were run at the constant voltage of 150V for 1h and silver staining was 
performed to visualize the bands according to the previously published protocol.61 A 0.1% human 
serum sample was also run for comparison. 
Cellular uptake. MCF7 cells (breast adenocarcinoma) were cultured at 37 °C under a 
humidified atmosphere of 5 % CO2. The cells were grown in low glucose Dulbecco’s Modified 
Eagle’s Medium (DMEM, 1.0 g/L glucose) containing 10 % fetal bovine serum (FBS) and 1% 
antibiotics (100 U/ml penicillin and 100 μg/ml streptomycin). For the uptake experiment, 20,000 
cells/well were plated in a 48-well plate prior to the experiment. On the following day, cells were 
washed one time with PBS followed by NP treatment (25 nM/well) and further incubated with or 
without 10% serum for 3 h (or 24 h). Following incubation, cells were lysed and the intracellular 
gold amount was measured using inductively coupled plasma mass spectrometry (Elan 6100, 
Perkin-Elmer, Shelton, CT, USA). Each cell uptake experiment was done in triplicate, and each 
replicate was measured 5 times by ICP-MS. ICP-MS operating conditions are as below: rf power 
1600 W; plasma Ar Flow rate, 15 ml/min, nebulizer Ar flow rate, 0.98 ml/min and dwell time, 45 
ms. 
Hemolysis. Red blood cells (RBCs) were purified from citrate-stabilized human whole 
blood (pooled, mixed gender) by multiple cycles of centrifugation and dilution in PBS (5000 
r.p.m., 5 min). The purified RBCs were then diluted in 10 mL of PBS and kept on ice during the 
sample preparation. 0.1 mL of RBC solution was added to 0.4 mL of NP solution in PBS in a 1.5 
mL centrifuge tube (Fisher) and mixed gently by pipetting (NPs at a final concentration of 250 
nM and 500 nM). RBCs incubated with PBS and water were used as negative and positive control 
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respectively. All NP samples as well as controls were prepared in triplicate. The mixture was 
incubated at 37 ˚C for 30 min, 6h and 24h while shaking at 150 r.p.m. After incubating, the 
solution was centrifuged at 4000 r.p.m. for 5 minutes and 100 μL of supernatant was transferred 
to a 96-well plate. The absorbance value of the supernatant was measured at 570 nm using a 
microplate reader (SpectraMax M2, Molecular Devices) with absorbance at 655 nm as a 
reference. To determine hemolysis in the presence of plasma, NPs were pre-incubated in 55% of 
plasma solution in PBS (v/v) for 30 minutes at 37 ˚C. After the pre-incubation period, 0.1 mL of 
washed RBCs were added to the solution and further incubated for 24 hours. The percent 
hemolysis was calculated using the following formula: 
%Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 
absorbance-negative control absorbance)) × 100. 
To corroborate that the lack of hemolytic properties was not due to precipitation of NPs 
in the presence of RBC, sedimentation experiments were done in PBS both in the presence and 
absence of RBCs. A control with no NPs was used to remove the background. As observed in 
Figure S23, the differences in the absorbance in the presence and absence of RBCs are not 
significant, indicating that NPs remained in the solution for both cases. 
Cell viability: The cell viability was determined by alamar blue assay according to 
manufacturer protocol (Life Technologies, DAL1100). MCF7 cells (15000 cells/well) were 
seeded in a 96-well plate 24 hours prior to the experiment. On the following day, the old media 
was aspirated and the cells were washed with PBS for one time. NPs ZMe-ZDiPen (25 nM each) 
were then incubated with the cells in 10% serum containing media for 24 h at 37 °C. After the 
incubation period, the cells were washed three times with PBS and 220 µL of 10 % alamar blue 
solution in serum containing media was added to each well and cells were further incubated at 37 
˚C for 3 hours. After 3 hours, 200 µL of solution from each well were taken out and loaded in a 
96- well black microplate. Red fluorescence, resulting from the reduction of the alamar blue 
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solution by viable cells was measured (Ex: 560 nm, Em: 590 nm) on a SpectroMax M2 
microplate reader (Molecular Device). Viability (%) of NP-treated cells was calculated taking 
untreated cells as 100 % viable. All experiments were performed using at least four parallel 
replicates.  
 
 
 
 
6.5. Supplementary Information 
 
Figure 6.4. DLS profiles (% Volume) of the series of NPs after incubation in 55% human serum 
and successive dilutions, evidencing the absence of protein corona for ZMe-ZDiPen while NP+, 
NP- and TEG present NP/protein complexes. 
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Figure 6.5. Agarose gel electrophoresis showing similar mobilities for NPs ZMe-ZDiPen in the 
presence and absence of plasma, while NP+ and NP- present a retarded band due to conjugation 
with proteins (a = NPs alone, p = mixture of plasma and NPs). NP concentration is 1 μM. 
 
 
Figure 6.6. (a) Sedimentation experiments at 10% and 55% plasma concentration. (b) UV 
differences (λ=506nm) of the supernatants before and after centrifugation in 10% serum 
evidencing the significant difference in sedimentation between TEG, NP+, NP- and ZMe to 
ZDiPen (p-values < 0.05). The sediment observed in the case of ZDiBu and ZDiPen were 
removed after washing with PBS 1-2 times indicating a reversible binding, while the positive 
control retained the pellet. 
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Figure 6.7. Gel electrophoresis of the samples obtained by the 24% sucrose sedimentation, 
evidencing very low level of proteins in the samples of the zwitterionic NPs (ZMe – ZDiPen, 
similar to control with no NP), while NP+ presented protein bands indicating corona formation. 
Serum lane indicates a sample with 0.1% serum directly loaded into the gel. 
 
Figure 6.8. %Viability of MCF7 cells at 24h for the different NPs. 
 
94 
 
6.6. References
 
1. Sapsford, K. E.; Algar, W. R.; Berti, L.; Gemmill, K. B.; Casey, B. J.; Oh, E.; Stewart, M. H.; 
Medintz, I. L. Chem. Rev. 2013, 113, 1904. 
2. Mout, R.; Moyano, D. F.; Rana, S.; Rotello, V. M. Chem. Soc. Rev. 2012, 41, 2539. 
3. Khlebtsov, N.; Dykman, L. Chem. Soc. Rev. 2011, 40, 1647. 
4. Kim, S. T.; Saha, K.; Kim, C.; Rotello, V. M. Acc. Chem. Res. 2013, 46, 681. 
5. He, X. X.; Nie, H. L.; Wang, K. M.; Tan, W. H.; Wu, X.; Zhang, P. F. Anal. Chem. 2008, 80, 
9597.  
6. Alexis, F.; Pridgen, E.; Molnar, L. K.; Farokhzad, O. C. Mol. Pharmaceutics. 2008, 5, 505.  
7. Walkey, C. D.; Chan, W. C. W. Chem. Soc. Rev. 2012, 41, 2780. 
8. Monopoli, M. P.; Aberg, C.; Salvati, A.; Dawson, K. A. Nat. Nanotechnol. 2012, 7, 779. 
9. Maiorano, G.; Sabella, S.; Sorce, B.; Brunetti, V.; Malvindi, M. A.; Cingolani, R.; Pompa, P. P. 
Acs Nano 2010, 4, 7481. 
10.  Pelaz, B.; Charron, G.; Pfeiffer, C.; Zhao, Y.; de la Fuente, J. M.; Liang, X.-J.; Parak, W. J.; 
Del Pino, P. Small, 2013, 9, 1573. 
11. Mahmoudi, M.; Lynch, I.; Ejtehadi, M. R.; Monopoli, M.P.; Bombelli, F. B.; Laurent, S. 
Chem. Rev. 2011, 111, 5610. 
12. Lundqvist, M.; Stigler, J.; Elia, G.; Lynch, I.; Cedervall, T.; Dawson, K. A. Proc. Natl. Acad. 
Sci. U.S.A. 2008, 105, 14265. 
13. Aggarwal, P.; Hall, J. B.; McLeland, C. B.; Dobrovolskaia, M. A.; McNeil, S. E. Adv. Drug 
Deliv. Rev. 2009, 61, 428. 
14. Tenzer, S.; Docter, D.; Kuharev, J.; Musyanovych, A.; Fetz, V.; Hecht, R.; Schlenk, F.; 
Fischer, D.; Kiouptsi, K.; Reinhardt, C.; Landfester, K.; Schild, H.; Maskos, M.; Knauer, S. K.; 
Stauber, R. H. Nat. Nanotechnol. 2013, 8, 772. 
 
95 
 
 
15. Mirshafiee, V.; Mahmoudi, M.; Lou, K. Y.; Cheng, J. J.; Kraft, M. L. Chem. Commun. 2013, 
49, 2557. 
16. Salvati, A.; Pitek, A. S.; Monopoli, M. P.; Prapainop, K.; Bombelli, F. B.; Hristov, D. R.; 
Kelly, P. M.; Aberg, C.; Mahon, E.; Dawson, K. A. Nat. Nanotechnol. 2013, 8, 137. 
17. Lesniak, A.; Fenaroli, F.; Monopoli, M. R.; Aberg, C.; Dawson, K. A.; Salvati, A. ACS Nano 
2012, 6, 5845.  
18. Zhu, Z. J.; Posati, T.; Moyano, D. F.; Tang, R.; Yan, B.; Vachet, R. W.; Rotello, V. M. Small 
2012, 8, 2659. 
19. Jokerst, J. V.; Lobovkina, T.; Zare, R. N.; Gambhir, S. S. Nanomedicine 2011, 6, 715.  
20. Karakoti, A. S.; Das, S.; Thevuthasan, S.; Seal, S. Angew. Chem. Int. Ed. 2011, 50, 1980. 
21. Hamad, I.; Al-Hanbali, O.; Hunter, A. C.; Rutt, K. J.; Andresen, T. L.; Moghimi, S. M. ACS 
Nano 2010, 4, 6629. 
22. Sekiguchi, S.; Niikura, K.; Matsuo, Y.; Ijiro, K. Langmuir 2012, 28, 5503. 
23. Rosen, J. E.; Gu, F. X. Langmuir 2011, 27, 10507. 
24. Yang, W.; Zhang, L.; Wang, S.; White, A. D.; Jiang, S. Y. Biomaterials 2009, 30, 5617. 
25. Cao, Z. Q.; Jiang, S. Y. Nano Today 2012, 7, 404.  
26. Murthy, A. K.; Stover, R. J.; Hardin, W. G.; Schramm, R.; Nie, G. D.; Gourisankar, S.; 
Truskett, T. M.; Sokolov, K. V.; Johnston, K. P. J. Am. Chem. Soc. 2013, 135, 7799. 
27. McCormick, C. L.; Lowe, A. B. Acc. Chem. Res. 2004, 37, 312.  
28. Matyjaszewski, K. Macromolecules 2012, 45, 4015.  
29. Arvizo, R. R.; Miranda, O. R.; Moyano, D. F.; Walden, C. A.; Giri, K.; Bhattacharya, R.; 
Robertson, J. D.; Rotello, V. M.; Reid, J. M.; Mukherjee, P. Plos One 2011, 6, e24374.  
30. Maiti, S.; Das, K.; Dutta, S.; Das, P. K. Chem. Eur. J. 2012, 18, 15021.  
31. Zuo, G.; Huang, Q.; Wei, G.; Zhou, R.; Fang, H. ACS Nano 2010, 4, 7508. 
32. Fubini, B.; Ghiazza, M.; Fenoglio, I. Nanotoxicology 2010, 4, 347. 
 
96 
 
 
33. Chompoosor, A.; Saha, K.; Ghosh, P. S.; Macarthy, D. J.; Miranda, O. R.; Zhu, Z. J.; Arcaro, 
K. F.; Rotello, V. M. Small 2010, 6, 2246. 
34. Moyano, D. F.; Goldsmith, M.; Solfiell, D. J.; Landesman-Milo, D.; Miranda, O. R.; Peer, D.; 
Rotello, V. M. J. Am. Chem. Soc. 2012, 134, 3965. 
35. Kreuter, J.; Liehl, E.; Berg, U.; Soliva, M.; Speiser, P. P. Vaccine 1988, 6, 253. 
36. Zhang, G.; Yang, Z.; Lu, W.; Zhang, R.; Huang, Q.; Tian, M.; Li, L.; Liang, D.; Li, C. 
Biomaterials 2009, 30, 1928.   
37. Rana, S.; Yu, X.; Patra, D.; Moyano, D. F.; Miranda, O. R.; Hussain, I.; Rotello, V. M. 
Langmuir 2012, 28, 2023. 
38. Xiao, Y.; Wiesner, M. R. J. Hazard. Mater. 2012, 215, 146. 
39. Zhang, C.; Macfarlane, R. J.; Young, K. L.; Choi, C. H. J.; Hao, L.; Auyeung, E.; Liu, G.; 
Zhou, X.; Mirkin, C. A. Nat. Mater. 2013, 12, 741. 
40. Milani, S.; Bombelli, F. B.; Pitek, A. S.; Dawson, K. A.; Rädler, J. ACS Nano 2012, 6, 2532. 
41. Casals, E.; Puntes, V. F. Nanomedicine 2012, 7, 1917. 
42. Monopoli, M. P.; Pitek, A. S.; Lynch, I.; Dawson, K. A. Methods Mol. Biol. 2013, 1025, 137. 
43.  Zhu, Z.-J.; Ghosh, P.; Miranda, O. R.; Vachet, R. W.; Rotello, V. M. J. Am. Chem. Soc. 
2008, 130, 14139. 
44. Mortimer, G. M.; Butcher, N. J.; Musumeci, A. W.; Deng, Z. J.; Martin, D. J.; Minchin, R. F. 
ACS Nano, 2014, 8, 3357. 
45. Walkey, C. D.; Olsen, J. B.; Song, F.; Liu, R.; Guo, H.; Olsen, D. W. H.; Cohen, Y.; Emili, 
A.; Chan, W. C. W. ACS Nano 2014, 8, 2439. 
46. Walkey, C.D.; Olsen, J.B.; Guo, H.; Emili, A.; Chan, W.C. J. Am. Chem. Soc. 2012, 134, 
2139.  
47. Gessner, A.; Waicz, R.; Lieske, A.; Paulke, B. R.; Mader, K.; Muller, R. H. Int. J. Pharm. 
2000, 196, 245. 
 
97 
 
 
48. Baier, G.; Costa, C.; Zeller, A.; Baumann, D.; Sayer, C.; Araujo, P. H. H.; Mailander, V.; 
Musyanovych, A.; Landfester, K. Macromol. Biosci. 2011, 11, 628. 
49. Patil, S.; Sandberg, A.; Heckert, E.; Self, W.; Seal, S. Biomaterials 2007, 28, 4600.  
50. Kim, C. K.; Ghosh, P.; Pagliuca, C.; Zhu, Z.-J.; Menichetti, S.; Rotello, V. M. J. Am. Chem. 
Soc. 2009, 131, 1360. 
51. Hühn, D.; Kantner, K.; Geidel, C.; Brandholt, S.; Cock, I. D.; Soenen, S. J. H.; Rivera_Gil, P.; 
Montenegro, J.-M.; Braeckmans, K.; Müllen, K. et al. ACS Nano 2013, 7, 3253.  
52. Fleischer, C. C.; Kumar, U.; Payne, C. K. Biomater. Sci. 2013, 1, 975. 
53. Xiao, W. C.; Lin, J.; Li, M. L.; Ma, Y. J.; Chen, Y. X.; Zhang, C. F.; Li, D.; Gu, H. C. 
Contrast Media Mol. Imaging 2012, 7, 320. 
54. Lin, Y. S.; Haynes, C. L. J. Am. Chem. Soc. 2010, 132, 4834.  
55. Lin, Y. S.; Haynes, C. L. Chem. Mater. 2009, 21, 3979.  
56. Saha, K.; Moyano, D. F.; Rotello, V. M. Mater. Horiz. 2014, 1, 102.  
57. Brust, M.; Walker, M.; Bethell, D.; Schiffrin, D. J.; Whyman, R. J. Chem. Soc. Chem. 
Commun. 1994, 7, 801. 
58. Moyano, D. F.; Duncan, B.; Rotello, V. M. Methods Mol. Biol. 2013, 1025, 3. 
59. Hostetler, M. J.; Green, S. J.; Stokes, J. J.; Murray, R. W. J. Am. Chem. Soc. 1996, 118, 4212. 
60. Liu, X.; Atwater, M.; Wang, J.; Huo,Q. Colloids Surf. B 2007, 58, 3. 
61. Chevallet, M.; Luche, S.; Rabilloud, T. Nat Protoc. 2006, 1, 1852. 
98 
 
CHAPTER 7 
ACYLSULFONAMIDE-FUNCTIONALIZED ZWITTERIONIC GOLD 
NANOPARTICLES FOR ENHANCED CELLULAR UPTAKE AT TUMOR PH 
7.1. Introduction 
The pH difference between normal tissue (pH 7.2-7.4) and tumor tissue (pH 6.0-6.8)1 
provides an attractive strategy for selective accumulation of nanoparticles (NPs) into tumor 
tissues for cancer treatment and/or imaging. To supply high tumor selectivity, a pH-responsive 
bio-interactive surface must be generated with appropriate responses at normal and tumor pH.2 
The most common strategy is the use of a non-interactive functional group bearing an acid-
cleavable unit; however, difficulty in controlling the acid sensitivity can result in the cleavage 
reaction taking place even at neutral pH,3 or requiring quite low pH (≈ 5.0) for activation.4 The 
use of reversible protonation/deprotonation systems provides an alternate strategy that features 
high tunablity.5 Recent reports employing polymers such as poly-histidine and poly-amine as a 
pH-responsive moiety provided high tumor pH sensitivity,6 demonstrating their utilities for tumor 
targeting. Solubility can be a challenge, however, with these neutral-to-cationic systems, 
requiring the use of additional functional group such as poly(ethylene)glycol chains to provide 
non-interactive surfaces at neutral pH. 
Zwitterionic surfaces have recently received considerable attention as non-interacting 
chemical surfaces.7 NPs with zwitterionic surfaces exhibit a long circulatory half-life,8 low 
cytotoxicity,9 and high biocompatibility. Integration of these properties with a pH dependent 
zwitterionic-to-cationic charge conversion system would make them attractive scaffolds for 
therapeutics. The low cellular uptake of zwitterionic particles10 makes them excellent candidates 
for pH-controlled tumor uptake upon protonation to the resulting cationic particle. Moreover, 
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concomitant cytotoxicity resulting from these cationic NPs11  would occur only in the tumor 
environment, leading to the possibility of tumor-selective therapy.  
 
Figure 7.1. Chemical structure of the monolayer-protected gold nanoparticles (AuNPs) and our 
strategy for a pH-responsive delivery system into tumors. 
A few examples of pH-responsive zwitterionic chemical surfaces such as 
carboxybetaine12 and phosphorylcholine have been reported.13 However, the pH-switching 
abilities of these structures are not sensitive enough to respond to stimuli such as weakly acidic 
tumor pH, with carboxybetaines protonated at pH <2 and phosphorylcholine at pH <5. The pKa 
value of the negatively and charged group is the key for precise pH-responsiveness, but has only 
been reported using mixed-monolayer particles featuring anionic and cationic ligands.14 Here, we 
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report a new pH-responsive zwitterionic surface structure engineered by derivatization of 
acylsulfonamide group. Due to its precise pKa value, this designed zwitterionic group becomes 
cationic at tumor pH (< 6.5), resulting in dramatically enhanced cellular uptake and cytotoxicity. 
Significantly, these particles show no hemolytic activity at physiological pH (7.4). 
7.2. Results and Discussion 
The acylsulfonamide group features pH behavior similar to that of carboxylic acid groups 
and has good metabolic stability.15 We chose this group as the negatively charged part of the 
zwitterionic ligand, with pH-responsiveness controlled by the functional group attached to the 
sulfonyl group. AuNP 1 features an aryl acylsulfonamide while AuNP 2 provides an alkyl analog 
(Figure 7.1). The ligands have trimethylammonium termini, and a tetra(ethylene glycol) spacer 
between the negative group and the hydrophobic chain was used as a passivating group to avoid 
irreversible adsorption and denaturation of serum proteins.16 These particles were synthesized 
from pentanethiol-capped AuNPs (ca. 2 nm core) by means of place-exchange reactions.17 
We initially measured zeta potential at several pH values to examine the pH dependence 
of the AuNP surface charges (Figure 7.2). The surface charge of both AuNP 1 and 2 were close to 
neutral at physiological pH (7.4), consistent with the zwitterionic structure of these NPs. AuNP 1 
features a sharp transition from neutral to cationic centered at pH 6.5. However, AuNP 2 
displayed a zwitterionic surface even at acidic pH, consistent with the reported pKa value of the 
acylsulfonamide group (pKa ≈ 4.5)18 and providing a permantly zwitterionic control particle for 
our studies. Recent reports on a pH-responsive zwitterionic AuNP with a mixed monolayer of 
carboxylic acid and quaternary ammonium ligands showed that the neutralization of surface 
charge during the charge alteration process results in the formation of precipitates.14,19 Therefore, 
we investigated if similar aggregates formed in our case. Dynamic light scattering data revealed 
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that no aggregation of these NPs was observed in the pH range from 7.4 to 6.0, preventing 
potential complications arising from particle aggregation.  
 
Figure 7.2. Zeta potential vs. pH curves obtained for AuNPs 1 and 2 (both 1 µM). Zeta-potentials 
were measured in 5 mM phosphate buffer at different pH values. Error bars represent standard 
deviations based on three independent measurements per pH value. 
The change of AuNP 1 from zwitterionic to positively charged surface at weakly acidic 
pH should enhance cellular uptake of AuNP. Both AuNPs 1 (switchable) and 2 (non-switchable) 
were incubated with HeLa cells for 3 h at three different pH values, with the resulting 
intracellular amount of gold measured using inductively coupled plasma mass spectrometry (ICP-
MS) (Figure 7.3). At pH 7.4, very low uptake (~10 ng/cell) was observed for both AuNPs 1 and 
2, similar to the cellular uptake of recently reported highly nonfouling sulfabetaine-functionalized 
AuNPs.7e Uptake of AuNP 1 increased with decreasing pH value, reaching a four-fold increase at 
pH 6.0. In contrast, no significant change in uptake was observed with control AuNP 2 over the 
pH range studied. Taken together, these studies establish the role of acylsulfonamide protonation 
in determining cellular uptake.  
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Figure 7.3. Cellular uptake of AuNPs 1 and 2 (both 1 μM ) after 3 h incubation with HeLa cells 
in the presence of 10% serum. All experiments were performed in triplicate, and error bars 
represent standard error of the mean. 
We next evaluated the cytotoxicity of AuNPs 1 and 2 at varying pH values using the 
Alamar blue viability assay (Figure 7.4). At pH 7.4, no cytotoxicity of AuNPs 1 and 2 was 
observed due to their non-interactive zwitterionic properties. Enhanced cytotoxicity of AuNP 1 
was observed at pH 6.6 and 6.0, as expected due to the conversion of the particle from 
zwitterionic to cationic.11 In contrast AuNP 2 did not show any significant toxicity at low pH 
values. While only a modest toxicity increase was observed at lower pH, these studies 
demonstrate the potential for this ligand in pH-regulated self-therapeutic. 
Hemolysis is an important issue for therapeutic nanomaterials.20 Therefore, we performed 
a hemolytic assay to investigate the blood compatibility of our NPs21 (Figure 7.5). AuNP-
mediated cell lysis events were not observed on either AuNP 1 or AuNP2. 
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Figure 7.4. Cell viability of HeLa cells after 72 h incubation with AuNPs 1 and 2 (both 1 μM) in 
the presence of 10% serum at different pH values. All experiments were performed in six 
replicates. Error bars represent standard error of the mean. 
 
Figure 7.5. Hemolytic activities of AuNP 1 and 2 (1 μM each) after 30 min of incubation with 
purified RBCs at 37 °C. % Hemolysis was calculated using water as positive control. All 
experiments were performed in triplicate. Error bars represent standard deviation.; NC = negative 
control (PBS); PC = positive control (water) 
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7.3. Conclusions 
We have developed a new pH-responsive zwitterionic ligand based on the alkoxyphenyl 
acylsulfonamide group. Due to its precisely designed surface structure, zwitterionic AuNPs 
functionalized with this ligand reversibly becomes cationic at tumor pH, with concomitant 
enhancement of cellular uptake and cytotoxicity. This combination of pH-regulated cellular 
uptake and cytotoxicity makes this ligand design promising for imaging, delivery, and self-
therapeutic applications.  
7.4. Experimental Section 
General: All the chemicals were purchased from Sigma-Aldrich or Fischer Scientific, 
unless otherwise specified. The chemicals were used as received. Dichloromethane (DCM) and 
tetrahydrofuran (THF) used as a solvent for chemical synthesis and dried according to standard 
procedures. The yields of the compounds reported here refer to the yields of spectroscopically 
pure compounds after purification. 1H NMR spectra were recorded at 400 MHz on a Bruker 
AVANCE 400 machine.  
Syntheses of Ligands: 
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4-((1,1,1-Triphenyl-14,17,20,23-tetraoxa-2-thiapentacosan-25-
yl)oxy)benzenesulfonamide (2). To a solution of 4-hydroxybenzenesulfonamide (332 mg, 1.92 
mmol) and NaOEt (560 μL, 1.73 mmol, 21 % EtOH solution) in EtOH (3.0 mL) and DMF (1.5 
mL) was added the solution of compound 122 (400 mg, 0.64 mmol) in DMF (1.5 mL) at rt. After 
being stirred at 60 °C for 18 h, EtOAc was added. The mixture was washed with sat. NaHCO3 (× 
3), H2O and brine, and dried over MgSO4. After concentration, the residue was purified by flash 
chromatography over silica gel with n-hexane–EtOAc (1:1 to 0:1) to give the desired compound 2 
as yellow oil (443 mg, 89%). 1H-NMR (400 MHz, CDCl3) 1.19-1.44 (16H, m, -CH2-), 1.55-1.61 
(2H, m, -CH2-), 2.15 (2H, t, J = 7.3 Hz, -SCH2-),3.45 (2H, t, J = 6.9 Hz, -OCH2-), 3.57-3.75 
(12H, m, -OCH2-), 3.89 (2H, t, J = 4.8 Hz, -OCH2-), 4.19 (2H, s, J = 4.6 Hz -OCH2-), 5.05 (2H, 
br s, -NH2), 6.98 (2H, d, J = 8.9 Hz, Ar), 7.20-7.31 (9H, m, Ar), 7.41-7.44 (6H, m, Ar), 7.85 (2H, 
d, J = 8.9Hz,Ar). MALDI-MS: m/z calculated for C44H59NNaO7S2 [M + Na]+ 800.363; found: 
800.459. 
 ({4-[(23-Mercapto-3,6,9,12-tetraoxatricosyl)oxy]phenyl}sulfonyl)[4-
(trimethylammonio)butanoyl]amide (Ligand 1). To a solution of compound 2 (1.0 g, 1.3 mmol), 
(3-carboxypropyl)-trimethylammonium chloride (519 mg, 2.86 mmol), DMAP (32 mg, 0.26 
mmol) and triethylamine (751 μL, 5.2 mmol) in DMF (6.5 mL) was added EDC·HCl (997 mg, 
5.2 mmol). After being stirred at rt for 1 days, EtOAc was added. The mixture was washed with 
the mixture of 0.1 M HCl and brine (1:1, × 2), and dried over MgSO4. After concentration, the 
residue was suspended in the mixture of n-hexane and Et2O (1:1), and sonicated. After 
centrifugation, the supernatant was removed. This n-hexane–Et2O-washing step was repeated 
three times. And residue was washed with Et2O for more three times. To a solution of residue in 
CH2Cl2 (6.0 mL) were added trifluoroacetic acid (2.0 mL) and triisopropylsilane (0.5 mL). After 
being stirred at rt for 10 min, the mixture was concentrated in vacuo. The residue was suspended 
in n-hexane, and sonicated. After centrifugation, the supernatant was removed. This n-hexane-
washing step was repeated five times to give the desired Ligand 1 as pale yellow oil (266 mg, 
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31%). 1H-NMR (400 MHz, CDCl3) 1.19-1.38 (14H, m, -CH2-), 1.53-1.63 (4H, m, -CH2-), 1.97 
(2H, br s, -CH2-), 2.49-2.54 (4H, m, -SCH2-, -COCH2-), 3.10 (9H, s, CH3), 3.31 (2H, br s, -CH2-
N+), 3.44 (2H, t, J = 6.9 Hz, -OCH2-), 3.56-3.71 (12H, m, -OCH2-), 3.86 (2H, br t, J = 4.0 Hz, -
OCH2-), 4.11 (2H, br t, J = 4.0 Hz, -OCH2-), 6.99 (2H, d, J = 8.7 Hz, Ar), 7.91 (2H, d, J = 8.7Hz, 
Ar). MALDI-MS: m/z calculated for C32H59N2O8S2 [M + H]+ 663.371; found: 663.398. 
Ligand 2: 
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N-[(3-Chloropropyl)sulfonyl]-1,1,1-triphenyl-14,17,20,23,26-pentaoxa-2-thiaoctacosan-
28-amide (4). To a solution of compound 323 (500 mg, 0.73mmol), 3-chloropropanesulfonamide24 
(230 mg, 1.5 mmol), N,N-dimethyl-4-aminopyridine (DMAP) (17.9 mg, 0.14 mmol) and 
triethylamine (211 μL, 1.5 mmol) in CH2Cl2 (7.3 mL) was added 1-(3-dimethylaminopropyl)-3-
ethylcarbodiimide hydrochloride (EDC·HCl) (280 mg, 1.46 mmol). After being stirred at rt for 
2.5 h, EtOAc was added. The mixture was washed with 0.1 M HCl and brine, and dried over 
MgSO4. After concentration, the residue was purified by flash chromatography over silica gel 
with n-hexane–EtOAc–AcOH (50:49:1 to 0:99:1) to give the desired compound 4 as colorless oil 
(399 mg, 66%). 1H-NMR (400 MHz, CDCl3) 1.13-1.44 (14H, m, -CH2-), 1.55-1.62 (4H, m, -CH2-
), 2.15 (2H, t, J = 7.3 Hz, -SCH2-), 2.31-2.37 (2H, m, -CH2-), 3.46 (2H, t, J = 6.9 Hz, -OCH2-), 
3.58-3.77 (20H, m, -OCH2-), 4.14 (2H, s, -OCH2-), 7.18-7.32 (9H, m, Ar), 7.41-7.44 (6H, m, Ar), 
10.36 (1H, br s, NH). MALDI-MS: m/z calculated for C43H62ClNNaO8S2 [M + Na]+ 842.350; 
found: 842.544. 
26-Mercapto-N-{[3-(trimethylamino)propyl]sulfonyl}-3,6,9,12,15-pentaoxahexacosan-1-
amide (Ligand 2) The compound 4 (200 mg, 0.12 mmol) was dissolved in trimethylamine-EtOH 
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(33 wt%, 1.16 mL). After being stirred at 50 °C for 3 days, CH2Cl2 and EtOAc were added to the 
reaction mixture. The mixture was washed with the mixture of 1M HCl and brine (1:1), and dried 
over MgSO4. After concentration, the residue was suspended in n-hexane, and sonicated. After 
centrifugation, the supernatant was removed. This n-hexane-washing step was repeated five 
times. To a solution of residue in CH2Cl2 (3.0 mL) were added trifluoroacetic acid (1.0 mL) and 
triisopropylsilane (0.25 mL). After being stirred at rt for 10 min, the mixture was concentrated in 
vacuo. The residue was suspended in n-hexane, and sonicated. After centrifugation, the 
supernatant was removed. This n-hexane-washing step was repeated five times to give the desired 
compound Ligand 2 as pale yellow oil (43.5 mg, 30%). 1H-NMR (400 MHz, CDCl3) 1.28-1.41 
(14H, m, -CH2-), 1.54-1.66 (4H, m, -CH2-), 2.38 (2H, br s, -CH2-), 2.54 (2H, q, J = 7.5 Hz, -
SCH2-), 3.22 (9H, s, CH3), 3.45 (2H, t, J = 6.9 Hz, -OCH2-), 3.56-3.74 (20H, m, -OCH2-), 4.20 
(2H, s, -OCH2-). MALDI-MS: m/z calculated for C27H57N2O8S2 [M + H]+ 601.356; found: 
601.304. 
Synthesis of Gold Nanoparticles and Characterization: 
AuNP 1: 
S O
O
(
  
)9 (
             
)4Au
S
O2
N
O
N
 
AuNP 1 was prepared through place-exchange reaction of 1-pentanethiolprotected 2 nm 
gold nanoparticle (Au-C5) according to previously reported procedure.25 Briefly, to the solution 
of Au-C5 (10 mg) in CH2Cl2 (1 mL) was added the solution of ligand 1 (30 mg) in CH2Cl2:MeOH 
(4:1, 3 mL). After being stirred at rt for 24 h, the solvent was evaporated in vacuo. After 
nanoparticle residue was washed with EtOAc (10 mL × 3), the nanoparticle was immediately 
dissolved in MilliQ water and the aqueous solution of the nanoparticle was purified by dialysis 
with distilled water using SnakeSkinTM Dialysis Tubing (Thermo Scientific, 10,000 MWCO).; 
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MALDI-MS: m/z calculated for C32H59N2O8S2 [M + H]+ 663.371; found: 663.612., m/z calculated 
for C37H69N2O8S3 [M + S-C5H11]+ 765.421; found: 765.718. 
AuNP 2: 
S O
O
(
  
)9 (
             
)4
O
N
O2
S N
Au  
AuNP 2 was prepared by following the similar procedure with AuNP 1.; MALDI-MS: 
m/z calculated for C27H57N2O8S2 [M + H]+ 601.355; found: 601.443., m/z calculated for 
C32H67N2O8S3 [M + S-C5H11]+ 703.405; found: 703.659. 
Cell Culture: HeLa cells were cultured in low glucose Dulbecco’s Modified Eagle’s 
Medium (Life technologies, 10567-022) supplemented with 10% fetal bovine serum (Atlanta 
Biologicals, S11550) and 1% antibiotics (Cellgro, 30-004-CI). Cells were maintained at 37 °C 
under a humidified atmosphere with 5% CO2 and subcultured once every four days. 
Cellular uptake: 30,000 cells/well were plated in a 24-well plate prior to the experiment. 
On the following day, cells were washed one time with phosphate buffered saline (PBS) and 
incubated with AuNP 1 and AuNP 2 (1 μM each) in 10% serum containing media (pH 7.4, 6.6, 
and 6.0) for 3 h at 37 °C. After incubation, cells were washed three times with PBS and lysis 
buffer was added to each well. All lysed cell samples were then further processed for ICP-MS 
analysis (vide infra) to determine the intracellular amount of gold. Uptake experiments were 
performed independently at least two times and each experiment was comprised of three 
replicates. 
Sample preparation for ICP-MS and ICP-MS instrumentation: After cellular uptake, 
the lysed cells were transferred to 15 mL centrifuge tubes. 0.5 mL of fresh aqua regia (highly 
corrosive and must be used with extreme caution!) were added to each sample. Each sample was 
then diluted to 10 mL with de-ionized water. A series of gold standard solutions (0, 0.2, 0.5, 1, 2, 
5, 10, and 20 ppb) were prepared before the ICP-MS measurements. Each gold standard solution 
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also contained 5% aqua regia. The gold standard solutions and cellular uptake sample solutions 
were measured on a Perkin-Elmer NexION 300X ICP mass spectrometer. 197Au was measured 
under standard mode. Operating conditions are listed as below: nebulizer flow rate: 0.95-1 L/min; 
rf power: 1600 W; plasma Ar flow rate: 18 L/min; dwell time: 50 ms. 
Cell proliferation assay: The cell proliferation was determined by alamar blue assay 
according to manufacturer protocol (Life Technologies, DAL1100). HeLa cells (5000 cells/well) 
were seeded in a 96-well plate 24 hours prior to the experiment. On the following day, the old 
media was aspirated and the cells were washed with PBS for one time. AuNP 1 and AuNP 2 (1 
μM each) were then incubated with the cells in 10% serum containing media (pH 7.4, 6.6, and 
6.0) for 72 h at 37 °C. After the incubation period, the cells were washed three times with PBS 
and 220 µL of 10 % alamar blue solution in serum containing media was added to each well and 
cells were further incubated at 37 ˚C for 4 hours. After 4 hours, 200 µL of solution from each 
well were taken out and loaded in a 96- well black microplate. Red fluorescence, resulting from 
the reduction of the alamar blue solution by viable cells was measured (Ex: 560 nm, Em: 590 nm) 
on a SpectroMax M2 microplate reader (Molecular Device). Viability (%) of NP-treated cells was 
calculated taking untreated cells as 100 % viable. All proliferation experiments were performed 
independently at least three times and each experiment was comprised of six replicates.  
Hemolysis: Citrate-stabilized human whole blood (pooled, mixed gender) was purchased 
from Bioreclamation LLC, NY and processed as soon as received. 10 mL of phosphate buffered 
saline (PBS) was added to the blood and centrifuged at 5000 r.pm. for 5 minutes. The supernant 
was carefully discarded and the red blood cells (RBCs) were dispersed in 10 mL of PBS. This 
step was repeated at least five times. The purified RBCs were diluted in 10 mL of PBS and kept 
on ice during the sample preparation. 0.1 mL of RBC solution was added to 0.4 mL of 
nanoparticle (NP) solution in PBS in 1.5 mL centrifuge tube (Fisher) and mixed gently by 
pipetting. RBCs incubated with PBS and water were used as negative and positive control, 
respectively. All NP samples as well as controls were prepared in triplicate. The mixture was 
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incubated at 37 ˚C for 30 minutes while shaking at 150 r.p.m. After incubation period, the 
solution was centrifuged at 4000 r.p.m. for 5 minutes and 100 μL of supernatant was transferred 
to a 96-well plate. The absorbance value of the supernatant was measured at 570 nm using a 
microplate reader (SpectraMax M2, Molecular devices) with absorbance at 655 nm as a 
reference. The percent hemolysis was calculated using the following formula: 
% Hemolysis = ((sample absorbance-negative control absorbance)) / ((positive control 
absorbance-negative control absorbance)) × 100. 
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